

**(12) STANDARD PATENT  
(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2003301585 B2**

(54) Title  
**Nucleic acids, polypeptides, and methods for modulating apoptosis**

(51) International Patent Classification(s)  
**C07K 14/47** (2006.01)      **C12Q 1/68** (2006.01)

(21) Application No: **2003301585**      (22) Date of Filing: **2003.10.22**

(87) WIPO No: **WO04/037984**

(30) Priority Data

(31) Number  
**10/277,969**      (32) Date  
**2002.10.23**      (33) Country  
**US**

(43) Publication Date: **2004.05.13**  
(43) Publication Journal Date: **2004.06.17**  
(44) Accepted Journal Date: **2009.08.20**

(71) Applicant(s)  
**Senesco Technologies, Inc.**

(72) Inventor(s)  
**Pomerantz, Benjamin; Taylor, Catherine; Dinarello, Charles; Thompson, John E.; Reznikov, Leonid; Cliche, Dominic**

(74) Agent / Attorney  
**Shelston IP, 60 Margaret Street, Sydney, NSW, 2000**

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number  
WO 2004/037984 A3

(51) International Patent Classification<sup>7</sup>: A61K 48/00, (81) Designated States (national): AE, AG, AL, AM, AT, AU, C12Q 1/68, C07H 21/04 AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US2003/033463

(22) International Filing Date: 22 October 2003 (22.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/277,969 23 October 2002 (23.10.2002) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: SENESCO TECHNOLOGIES, INC. [US/US]; 303 George Street, New Brunswick, NJ 08901 (US).

(72) Inventors: THOMPSON, John, E.; 901 University Ave. E., Waterloo, Ontario N2K 4N1 (CA). TAYLOR, Catherine; 122 Foxhunt Rd., Waterloo, Ontario N2K 3N1 (CA). CLICHE, Dominic; 52-75 Old Chicopee Dr., Unit # 52, Kitchener, Ontario N2A 2G4 (CA). DINARELLO, Charles; 333 15th Street, Boulder, CO 80302 (US). REZNIKOV, Leonid; 4098 S. Sable Cir., Aurora, CO 80014 (US). POMERANTZ, Benjamin; 7143 Cornell Ave., University City, MO 63130 (US).

(74) Agents: LAVENUE, Teresa, A. et al.; KENYON & KENYON, 1500 K Street N.W., Suite 700, Washington, DC 20005-1257 (US).

#### Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

14 April 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/037984 A3

(54) Title: NUCLEIC ACIDS, POLYPEPTIDES, AND METHODS FOR MODULATING APOPTOSIS

(57) Abstract: The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heart tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5A is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.

NUCLEIC ACIDS, POLYPEPTIDES, AND METHODS FOR  
MODULATING APOPTOSIS  
RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application serial number 5 10/200,148, filed on July 23, 2002, which is a continuation-in-part of U.S. application serial number 10/141,647, filed May 7, 2002, which is a continuation-in part of U.S. application serial number, 9/909,796, filed July 23, 2001.

FIELD OF THE INVENTION

The present invention relates to apoptosis-specific eucaryotic initiation Factor-10 5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides and methods for modulating apoptosis in cells using apoptosis-specific eIF-5A and DHS.

BACKGROUND OF THE INVENTION

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common 15 general knowledge in the field.

Apoptosis is a genetically programmed cellular event that is characterized by well-defined morphological features, such as cell shrinkage, chromatin condensation, nuclear fragmentation, and membrane blebbing. Kerr et al. (1972) *Br. J. Cancer*, **26**, 239-257; Wyllie et al. (1980) *Int. Rev. Cytol.*, **68**, 251-306. It plays an important role in 20 normal tissue development and homeostasis, and defects in the apoptotic program are thought to contribute to a wide range of human disorders ranging from neurodegenerative and autoimmunity disorders to neoplasms. Thompson (1995) *Science*, **267**, 1456-1462; Mullauer et al. (2001) *Mutat. Res.*, **488**, 211-231. Although the 25 morphological characteristics of apoptotic cells are well characterized, the molecular pathways that regulate this process have only begun to be elucidated.

One group of proteins that is thought to play a key role in apoptosis is a family of cysteine proteases, termed caspases, which appear to be required for most pathways of apoptosis. Creagh & Martin (2001) *Biochem. Soc. Trans.*, **29**, 696-701; Dales et al. (2001) *Leuk. Lymphoma*, **41**, 247-253. Caspases trigger apoptosis in response to 30 apoptotic stimuli by cleaving various cellular proteins, which results in classic manifestations of apoptosis, including cell shrinkage, membrane blebbing and DNA fragmentation. Chang & Yang (2000) *Microbiol. Mol. Biol. Rev.*, **64**, 821-846.

Pro-apoptotic proteins, such as Bax or Bak, also play a key role in the apoptotic pathway by releasing caspase-activating molecules, such as mitochondrial cytochrome c, thereby promoting cell death through apoptosis. Martinou & Green (2001) *Nat. Rev. Mol. Cell. Biol.*, **2**, 63-67; Zou et al. (1997) *Cell*, **90**, 405-413. Anti-apoptotic proteins, such as 5 Bcl-2, promote cell survival by antagonizing the activity of the pro-apoptotic proteins, Bax and Bak. Tsujimoto (1998) *Genes Cells*, **3**, 697-707; Kroemer (1997) *Nature Med.*, **3**, 614-620. The ratio of Bax:Bcl-2 is thought to be one way in which cell fate is determined; an excess of Bax promotes apoptosis and an excess of Bcl-2 promotes cell survival. Salomons et al. (1997) *Int. J. Cancer*, **71**, 959-965; Wallace-Brodeur & Lowe (1999) *Cell Mol. Life Sci.*, **55**, 64-75.

Another key protein involved in apoptosis is that encoded by the tumor suppressor gene p53. This protein is a transcription factor that regulates cell growth and induces apoptosis in cells that are damaged and genetically unstable, presumably through up-regulation of Bax. Bold et al. (1997) *Surgical Oncology*, **6**, 133-142; Ronen et al., 1996; 15 Schuler & Green (2001) *Biochem. Soc. Trans.*, **29**, 684-688; Ryan et al. (2001) *Curr. Opin. Cell Biol.*, **13**, 332-337; Zörnig et al. (2001) *Biochem. Biophys. Acta*, **1551**, F1-F37.

The distinct morphological features that characterize cells undergoing apoptosis have given rise to a number of methods for assessing the onset and progress of apoptosis. One such feature of apoptotic cells that can be exploited for their detection is activation of 20 a flippase, which results in externalization of phosphatidylserine, a phospholipid normally localized to the inner leaflet of the plasma membrane. Fadok et al. (1992) *J. Immunol.*, **149**, 4029-4035. Apoptotic cells bearing externalized phosphatidylserine can be detected by staining with a phosphatidylserine-binding protein, Annexin V, conjugated to a fluorescent dye. The characteristic DNA fragmentation that occurs during the apoptotic 25 process can be detected by labeling the exposed 3'-OH ends of the DNA fragments with fluorescein-labeled deoxynucleotides. Fluorescent dyes that bind nucleic acids, such as Hoescht 33258, can be used to detect chromatin condensation and nuclear fragmentation in apoptotic cells. The degree of apoptosis in a cell population can also be inferred from the extent of caspase proteolytic activity present in cellular extracts.

30 As a genetically defined process, apoptosis, like any other developmental program, can be disrupted by mutation. Alterations in the apoptotic pathways are believed to play a key role in a number of disease processes, including cancer. Wyllie et al. (1980) *Int. Rev.*

*Cytol.*, **68**, 251-306; Thompson (1995) *Science*, **267**, 1456-1462; Sen & D'Incalci (1992) *FEBS Letters*, **307**, 122-127; McDonnell et al. (1995) *Seminars in Cancer and Biology*, **6**, 53-60. Investigations into cancer development and progression have traditionally been focused on cellular proliferation. However, the important role that apoptosis plays in 5 tumorigenesis has recently become apparent. In fact, much of what is now known about apoptosis has been learned using tumor models, since the control of apoptosis is invariably altered in some way in tumor cells. Bold et al. (1997) *Surgical Oncology*, **6**, 133-142.

Apoptosis can be triggered during tumor development by a variety of signals. Extracellular signals include growth or survival factor depletion, hypoxia and ionizing 10 radiation. Internal signals that can trigger apoptosis include DNA damage, shortening telomeres, and oncogenic mutations that produce inappropriate proliferative signals. Lowe & Lin (2000) *Carcinogenesis*, **21**, 485-495. Ionizing radiation and nearly all cytotoxic chemotherapy agents used to treat malignancies are thought to act by triggering 15 endogenous apoptotic mechanisms to induce cell death. Rowan & Fisher (1997) *Leukemia*, **11**, 457-465; Kerr et al. (1994) *Cancer*, **73**, 2013-2026; Martin & Schwartz (1997) *Oncology Research*, **9**, 1-5.

Evidence would suggest that early in the progression of cancer, tumor cells are 20 sensitive to agents (such as ionizing radiation or chemotherapeutic drugs) that induce apoptosis. However, as the tumor progresses, the cells develop resistance to apoptotic stimuli. Naik et al. (1996) *Genes and Development*, **10**, 2105-2116. This may explain why early cancers respond better to treatment than more advanced lesions. The ability of 25 late-stage cancers to develop resistance to chemotherapy and radiation therapy appears to be linked to alterations in the apoptotic pathway that limit the ability of tumor cells to respond to apoptotic stimuli. Reed et al. (1996) *Journal of Cellular Biology*, **60**, 23-32; Meyn et al. (1996) *Cancer Metastasis Reviews*, **15**, 119-131; Hannun (1997) *Blood*, **89**, 1845-1853; Reed (1995) *Toxicology Letters*, **82-83**, 155-158; Hickman (1996) *European Journal of Cancer*, **32A**, 921-926. Resistance to chemotherapy has been correlated to overexpression of the anti-apoptotic gene bcl-2 and deletion or mutation of the pro-apoptotic bax gene in chronic lymphocytic leukemia and colon cancer, respectively.

30 The ability of tumor cells to successfully establish disseminated metastases also appears to involve alterations in the apoptotic pathway. Bold et al. (1997) *Surgical Oncology*, **6**, 133-142. For example, mutations in the tumor suppressor gene p53 are

thought to occur in 70 % of tumors. Evan et al. (1995) *Curr. Opin. Cell Biol.*, **7**, 825-834. Mutations that inactivate p53 limit the ability of cells to induce apoptosis in response to DNA damage, leaving the cell vulnerable to further mutations. Ko & Prives (1996) *Genes and Development*, **10**, 1054-1072.

5 Therefore, apoptosis is intimately involved in the development and progression of neoplastic transformation and metastases, and a better understanding of the apoptotic pathways involved may lead to new potential targets for the treatment of cancer by the modulation of apoptotic pathways through gene therapy approaches. Bold et al. (1997) *Surgical Oncology*, **6**, 133-142.

10 Deoxyhypusine synthase (DHS) and hypusine-containing eucaryotic translation initiation Factor-5A (eIF-5A) are known to play important roles in many cellular processes including cell growth and differentiation. Hypusine, a unique amino acid, is found in all examined eucaryotes and archaebacteria, but not in eubacteria, and eIF-5A is the only known hypusine-containing protein. Park (1988) *J. Biol. Chem.*, **263**, 7447-7449; Schümann & Klink (1989) *System. Appl. Microbiol.*, **11**, 103-107; Bartig et al. (1990) *System. Appl. Microbiol.*, **13**, 112-116; Gordon et al. (1987a) *J. Biol. Chem.*, **262**, 16585-16589. Active eIF-5A is formed in two post-translational steps: the first step is the formation of a deoxyhypusine residue by the transfer of the 4-aminobutyl moiety of spermidine to the  $\alpha$ -amino group of a specific lysine of the precursor eIF-5A catalyzed by 20 deoxyhypusine synthase; the second step involves the hydroxylation of this 4-aminobutyl moiety by deoxyhypusine hydroxylase to form hypusine.

The amino acid sequence of eIF-5A is well conserved between species, and there is strict conservation of the amino acid sequence surrounding the hypusine residue in eIF-5A, which suggests that this modification may be important for survival. Park et al. (1993) *Biofactors*, **4**, 95-104. This assumption is further supported by the observation that inactivation of both isoforms of eIF-5A found to date in yeast, or inactivation of the DHS gene, which catalyzes the first step in their activation, blocks cell division. Schnier et al. (1991) *Mol. Cell. Biol.*, **11**, 3105-3114; Sasaki et al. (1996) *FEBS Lett.*, **384**, 151-154; Park et al. (1998) *J. Biol. Chem.*, **273**, 1677-1683. However, depletion of eIF-5A protein 30 in yeast resulted in only a small decrease in total protein synthesis suggesting that eIF-5A may be required for the translation of specific subsets of mRNA's rather than for protein global synthesis. Kang et al. (1993), "Effect of initiation factor eIF-5A depletion on cell

proliferation and protein synthesis," in Tuite, M. (ed.), *Protein Synthesis and Targeting in Yeast*, NATO Series H. The recent finding that ligands that bind eIF-5A share highly conserved motifs also supports the importance of eIF-5A. Xu & Chen (2001) *J. Biol. Chem.*, **276**, 2555-2561. In addition, the hypusine residue of modified eIF-5A was found 5 to be essential for sequence-specific binding to RNA, and binding did not provide protection from ribonucleases.

The first cDNA for eIF-5A was cloned from human in 1989 by Smit-McBride et al., and since then cDNAs or genes for eIF-5A have been cloned from various eukaryotes including yeast, rat, chick embryo, alfalfa, and tomato. Smit-McBride et al. (1989a) *J. Biol. Chem.*, **264**, 1578-1583; Schnier et al. (1991) (yeast); Sano, A. (1995) in Imahori, M. et al. (eds), *Polyamines, Basic and Clinical Aspects*, VNU Science Press, The Netherlands, 81-88 (rat); Rinaudo & Park (1992) *FASEB J.*, **6**, A453 (chick embryo); Pay et al. (1991) *Plant Mol. Biol.*, **17**, 927-929 (alfalfa); Wang et al. (2001) *J. Biol. Chem.*, **276**, 17541-17549 (tomato).

15 In addition, intracellular depletion of eIF-5A resulted in a significant accumulation of specific mRNAs in the nucleus, indicating that eIF-5A may be responsible for shuttling specific classes of mRNAs from the nucleus to the cytoplasm. Liu & Tartakoff (1997) Supplement to *Molecular Biology of the Cell*, **8**, 426a. Abstract No. 2476, 37<sup>th</sup> American Society for Cell Biology Annual Meeting. The accumulation of eIF-5A at nuclear pore-20 associated intranuclear filaments and its interaction with a general nuclear export receptor further suggest that eIF-5A is a nucleocytoplasmic shuttle protein, rather than a component of polysomes. Rosorius et al. (1999) *J. Cell Science*, **112**, 2369-2380.

25 Expression of eIF-5A mRNA has been explored in various human tissues and mammalian cell lines. For example, changes in eIF-5A expression have been observed in human fibroblast cells after addition of serum following serum deprivation. Pang & Chen (1994) *J. Cell Physiol.*, **160**, 531-538. Age-related decreases in deoxyhypusine synthase activity and abundance of precursor eIF-5A have also been observed in senescent fibroblast cells, although the possibility that this reflects averaging of differential changes in isoforms was not determined. Chen & Chen (1997b) *J. Cell Physiol.*, **170**, 248-254.

30 Studies have shown that eIF-5A may be the cellular target of viral proteins such as the human immunodeficiency virus type 1 Rev protein and human T cell leukemia virus type 1 Rex protein. Ruhl et al. (1993) *J. Cell Biol.*, **123**, 1309-1320; Katahira et al. (1995)

*J. Virol.*, **69**, 3125-3133. Preliminary studies indicate that eIF-5A may target RNA by interacting with other RNA-binding proteins such as Rev, suggesting that these viral proteins may recruit eIF-5A for viral RNA processing. Liu et al. (1997) *Biol. Signals*, **6**, 166-174.

5 Deoxyhypusine synthase and eIF-5A are known to play important roles in key cellular processes including cell growth and senescence. For example, antisense reduction of deoxyhypusine synthase expression in plants results in delayed senescence of leaves and fruits, indicating that there is a senescence-inducing isoform of eIF-5A in plants. See WO 01/02592; PCT/US01/44505; U.S. Application No. 09/909,796. Inactivation of the genes 10 for deoxyhypusine synthase or eIF-5A in yeast results in inhibition of cell division. Schnier et al. (1991) *Mol. Cell. Biol.*, **11**, 3105-3114; Sasaki et al. (1996) *FEBS Lett.*, **384**, 151-154; Park et al. (1998) *J. Biol. Chem.*, **273**, 1677-1683.

15 Spermidine analogs have been successfully used to inhibit deoxyhypusine synthase *in vitro*, as well as to inhibit the formation of hypusine *in vivo*, which is accompanied by an inhibition of protein synthesis and cell growth. Jakus et al. (1993) *J. Biol. Chem.*, **268**, 13151-13159; Park et al. (1994) *J. Biol. Chem.*, **269**, 27827-27832. Polyamines themselves, in particular putrescine and spermidine, also appear to play important roles in 20 cellular proliferation and differentiation. Tabor & Tabor (1984) *Annu. Rev. Biochem.*, **53**, 749-790; Pegg (1988) *Cancer Res.*, **48**, 759-774. For example, yeast mutants in which the polyamine biosynthesis pathway has been blocked are unable to grow unless provided with 25 exogenous polyamines. Cohn et al. (1980) *J. Bacteriol.*, **134**, 208-213.

Polyamines have also been shown to protect cells from the induction of apoptosis. For example, apoptosis of thymocytes has been blocked by exposure to spermidine and spermine, the mechanism of which appears to be the prevention of endonuclease 25 activation. Desiderio et al. (1995) *Cell Growth Differ.*, **6**, 505-513; Brune et al. (1991) *Exp. Cell Res.*, **195**, 323-329. In addition, exogenous polyamines have been shown to repress B cell receptor-mediated apoptosis as well as apoptosis in the unicellular parasite, *Trypanosoma cruzi*. Nitta et al. (2001) *Exptl. Cell Res.*, **265**, 174-183; Piacenza et al. (2001) *Proc. Natl. Acad. Sci., USA*, **98**, 7301-7306. Low concentrations of spermine and 30 spermidine have also been observed to reduce the number of nerve cells lost during normal development of newborn rats, as well as protect the brain from neuronal damage during cerebral ischaemia. Gilad et al. (1985) *Brain Res.*, **348**, 363-366; Gilad & Gilad (1991)

*Exp. Neurol.*, **111**, 349-355. Polyamines also inhibit senescence, a form of programmed cell death, of plant tissues. Spermidine and putrescine have been shown to delay post-harvest senescence of carnation flowers and detached radish leaves. Wang & Baker (1980) *HortScience*, **15**, 805-806 (carnation flowers); Altman (1982) *Physiol. Plant.*, **54**, 189-193 (detached radish leaves).

In other studies, however, induction of apoptosis has been observed in response to exogenous polyamines. For example, human breast cancer cell lines responded to a polyamine analogue by inducing apoptosis, and excess putrescine has been shown to induce apoptosis in DH23A cells. McCloskey et al. (1995) *Cancer Res.*, **55**, 3233-3236; 10 Tome et al. (1997) *Biochem. J.*, **328**, 847-854.

The results from these experiments with polyamines collectively suggest that existence of specific isoforms of eIF-5A play a role in induction of apoptosis. Specifically, the data are consistent with the view that there is an apoptosis-specific isoform of eIF-5A, which is activated by DHS. The fact that this DHS reaction requires spermidine is 15 consistent with the finding that polyamines have been shown to elicit activation of caspase, a key executor of apoptosis-related proteolysis. Stefanelli et al. (2000) *Biochem. J.*, **347**, 875-880; Stefanelli et al. (1999) *FEBS Lett.*, **451**, 95-98. In a similar vein, inhibitors of polyamine synthesis can delay apoptosis. Das et al. (1997) *Oncol. Res.*, **9**, 565-572; Monti et al. (1998) *Life Sci.*, **72**, 799-806; Ray et al. (2000) *Am. J. Physiol.*, **278**, C480-C489; 20 Packham & Cleveland (1994) *Mol. Cell Biol.*, **14**, 5741-5747.

The finding that exogenous polyamines both inhibit and promote apoptosis can be explained by the fact that, depending upon the levels applied, they can either inhibit the DHS reaction leading to activation of eIF-5A and hence impede apoptosis, or induce apoptosis by reason of being toxic. The finding that low concentrations of exogenous 25 polyamines block apoptosis in plant and animal systems is consistent with the fact that low concentrations of polyamines and their analogues act as competitive inhibitors of the DHS reaction. Indeed, even exogenous spermidine, which is a substrate for the DHS reaction, will impede the reaction through substrate inhibition. Jakus et al. (1993) *J. Biol. Chem.*, **268**, 13153-13159.

30 However, all polyamines, and their analogues, are toxic at high concentrations and are able to induce apoptosis. This occurs despite their ability to inhibit activation of the putative apoptosis-specific isoform of eIF-5A for two reasons. First, activated eIF-5A has

a long half-life. Torrelio et al. (1987) *Biochem. Biophys. Res. Commun.*, **145**, 1335-1341; Dou & Chen (1990) *Biochim. Biophys. Acta.*, **1036**, 128-137. Accordingly, depletion of activated apoptosis-specific eIF-5A arising from inhibition of deoxyhypusine synthase activity may not occur in time to block apoptosis caused by the toxic effects of spermidine.

5 Second, polyamines are competitive inhibitors of the deoxyhypusine reaction and hence not likely to completely block the reaction even at concentrations that are toxic.

The present invention relates to cloning of an eIF-5A cDNA that is up regulated immediately before the induction of apoptosis. This apoptosis-specific eIF-5A is likely to be a suitable target for intervention in apoptosis-causing disease states since it appears to 10 act at the level of post-transcriptional regulation of downstream effectors and transcription factors involved in the apoptotic pathway. Specifically, the apoptosis-specific eIF-5A appears to selectively facilitate the translocation of mRNAs encoding downstream effectors and transcription factors of apoptosis from the nucleus to the cytoplasm, where they are subsequently translated. The ultimate decision to initiate apoptosis appears to 15 stem from a complex interaction between internal and external pro- and anti-apoptotic signals. Lowe & Lin (2000) *Carcinogenesis*, **21**, 485-495. Through its ability to facilitate the translation of downstream apoptosis effectors and transcription factors, the apoptosis-related eIF-5A appears to tip the balance between these signals in favor of apoptosis.

As described previously, it is well established that anticancer agents induce 20 apoptosis and that alterations in the apoptotic pathways can attenuate drug-induced cell death. Schmitt & Lowe (1999) *J. Pathol.*, **187**, 127-137. For example, many anticancer drugs upregulate p53, and tumor cells that have lost p53 develop resistance to these drugs. However, nearly all chemotherapy agents can induce apoptosis independently of p53 if the dose is sufficient, indicating that even in drug-resistant tumors, the pathways to apoptosis 25 are not completely blocked. Wallace-Brodeur & Lowe (1999) *Cell Mol. Life Sci.*, **55**, 64-75. This suggests that induction of apoptosis eIF-5A, even though it may not correct the mutated gene, may be able to circumvent the p53-dependent pathway and induce apoptosis by promoting alternative pathways.

Induction of apoptosis-related eIF-5A has the potential to selectively target cancer 30 cells while having little or no effect on normal neighboring cells. This arises because mitogenic oncogenes expressed in tumor cells provide an apoptotic signal in the form of specific species of mRNA that are not present in normal cells. Lowe et al. (1993) *Cell*, **74**,

954-967; Lowe & Lin (2000) *Carcinogenesis*, **21**, 485-495. For example, restoration of wild-type p53 in p53-mutant tumor cells can directly induce apoptosis as well as increase drug sensitivity in tumor cell lines and xenographs. (Spitz et al., 1996; Badie et al., 1998).

5 The selectivity of apoptosis-eIF-5A arises from the fact that it selectively facilitates translation of mRNAs for downstream apoptosis effectors and transcription factors by mediating their translocation from the nucleus into the cytoplasm. Thus, for apoptosis eIF-5A to have an effect, mRNAs for these effectors and transcription factors have to be transcribed. Inasmuch as these mRNAs would be transcribed in cancer cells, 10 but not in neighboring normal cells, it is to be expected that apoptosis eIF-5A would promote apoptosis in cancer cells but have minimal, if any, effect on normal cells. Thus, restoration of apoptotic potential in tumor cells with apoptosis-related eIF-5A may decrease the toxicity and side effects experienced by cancer patients due to selective targeting of tumor cells. Induction of apoptotic eIF-5A also has the potential to 15 potentiate the response of tumor cells to anti-cancer drugs and thereby improve the effectiveness of these agents against drug-resistant tumors. This in turn could result in lower doses of anti-cancer drugs for efficacy and reduced toxicity to the patient.

#### SUMMARY OF INVENTION

20 The present invention provides isolated and/or purified rat apoptosis-specific eIF-5A and DHS nucleic acids and polypeptides and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS. The present invention also provides isolated and/or purified apoptosis-specific eIF-5A (also referred to herein as human eIF-5A1 or eIF5a). The present invention also provides isolated and/or purified 25 human eIF-5A2 (also referred to herein as proliferating eIF-5A or eIF5b). The present invention also provides methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS.

The present invention also provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of 30 reducing apoptosis in mammalian tissue, preferably heart tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In

the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A.

According to a first aspect, the present invention provides a method of identifying an incidence of ischemia in a mammalian tissue, the method comprising

- 5 a. measuring gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A in the tissue
- b. comparing the expression level of apoptosis-specific eIF5a with the expression levels of proliferating eIF-5A in the tissue
- c. correlating an incidence of ischemia in the tissue when the expression level

10 of apoptosis-specific eIF5a is higher than the expression level of proliferating eIF-5A.

According to a second aspect, the present invention provides a method of reducing apoptosis in mammalian tissue, the method comprising

- 15 a. measuring gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A in mammalian tissue
- b. comparing the levels of expression of apoptosis-specific eIF-5A with the expression levels of proliferating eIF-5A in the mammalian tissue
- c. correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5A is higher than the expression level of proliferating eIF-5A

20 d. providing to the heart tissue of a mammal an agent that inhibits expression of apoptosis-specific eIF-5A.

Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the 25 sense of "including, but not limited to".

#### BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 depicts the nucleotide sequence and derived amino acid sequence of the 3' end of rat apoptosis-specific eIF-5A.

Figure 2 depicts the nucleotide sequence and derived amino acid sequence of the 5' end of rat apoptosis-specific eIF-5A cDNA.

10 Figure 3 depicts the nucleotide sequence of rat corpus luteum apoptosis-specific eIF-5A full-length cDNA.

Figure 4 depicts the nucleotide sequence and derived amino acid sequence of the 3' end of rat apoptosis-specific DHS cDNA.

Figure 5 is an alignment of the full-length nucleotide sequence of rat corpus luteum apoptosis-specific eIF-5A cDNA with the nucleotide sequence of human eIF-5A

15 (Accession number BC000751 or NM\_001970, SEQ ID NO:3).

Figure 6 is an alignment of the full-length nucleotide sequence of rat corpus luteum apoptosis-specific eIF-5A cDNA with the nucleotide sequence of human eIF-5A (Accession number NM-020390, SEQ ID NO:4).

20 Figure 7 is an alignment of the full-length nucleotide sequence of rat corpus luteum apoptosis-specific eIF-5A cDNA with the nucleotide sequence of mouse eIF-5A (Accession number BC003889). Mouse nucleotide sequence (Accession number BC003889) is SEQ ID NO:5.

25 Figure 8 is an alignment of the derived full-length amino acid sequence of rat corpus luteum apoptosis-specific eIF-5A with the derived amino acid sequence of human eIF-5A (Accession number BC000751 or NM\_001970).

Figure 9 is an alignment of the derived full-length amino acid sequence of rat corpus luteum apoptosis-specific eIF-5A with the derived amino acid sequence of human eIF-5A (Accession number NM\_020390).

30 Figure 10 is an alignment of the derived full-length amino acid sequence of rat corpus luteum apoptosis-specific eIF-5A with the derived amino acid sequence of mouse eIF-5A (Accession number BC003889).

Figure 11 is an alignment of the partial-length nucleotide sequence of rat corpus luteum apoptosis-specific DHS cDNA with the nucleotide sequence of human DHS (Accession number BC000333, SEQ ID NO:8).

Figure 12 is a restriction map of rat corpus luteum apoptosis-specific eIF-5A  
5 cDNA.

Figure 13 is a restriction map of the partial-length rat apoptosis-specific DHS cDNA.

Figure 14 is a Northern blot (Figure 14A) and an ethidium bromide stained gel (Figure 14B) of total RNA probed with the  $^{32}\text{P}$ -dCTP-labeled 3'-end of rat corpus luteum  
10 apoptosis-specific eIF-5A cDNA.

Figure 15 is a Northern blot (Figure 15A) and an ethidium bromide stained gel (Figure 15B) of total RNA probed with the  $^{32}\text{P}$ -dCTP-labeled 3'-end of rat corpus luteum apoptosis-specific DHS cDNA.

Figure 16 depicts a DNA laddering experiment in which the degree of apoptosis in  
15 superovulated rat corpus lutea was examined after injection with PGF-2 $\alpha$ .

Figure 17 is an agarose gel of genomic DNA isolated from apoptosing rat corpus luteum showing DNA laddering after treatment of rats with PGF-2 $\alpha$ .

Figure 18 depicts a DNA laddering experiment in which the degree of apoptosis in dispersed cells of superovulated rat corpora lutea was examined in rats treated with  
20 spermidine prior to exposure to prostaglandin F-2 $\alpha$  (PGF-2 $\alpha$ ).

Figure 19 depicts a DNA laddering experiment in which the degree of apoptosis in superovulated rat corpus lutea was examined in rats treated with spermidine and/or PGF-2 $\alpha$ .

Figure 20 is a Southern blot of rat genomic DNA probed with  $^{32}\text{P}$ -dCTP-labeled  
25 partial-length rat corpus luteum apoptosis-specific eIF-5A cDNA.

Figure 21 depicts pHM6, a mammalian epitope tag expression vector (Roche Molecular Biochemicals).

Figure 22 is a Northern blot (Figure 22A) and ethidium bromide stained gel (Figure 22B) of total RNA isolated from COS-7 cells after induction of apoptosis by withdrawal of  
30 serum probed with the  $^{32}\text{P}$ -dCTP-labeled 3'-untranslated region of rat corpus luteum apoptosis-specific DHS cDNA.

Figure 23 is a flow chart illustrating the procedure for transient transfection of COS-7 cells.

Figure 24 is a Western blot of transient expression of foreign proteins in COS-7 cells following transfection with pHM6.

5 Figure 25 illustrates enhanced apoptosis as reflected by increased caspase activity when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation.

10 Figure 26 illustrates enhanced apoptosis as reflected by increased DNA fragmentation when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation.

Figure 27 illustrates detection of apoptosis as reflected by increased nuclear fragmentation when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation.

15 Figure 28 illustrates enhanced apoptosis as reflected by increased nuclear fragmentation when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation.

Figure 29 illustrates detection of apoptosis as reflected by phosphatidylserine exposure when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation.

20 Figure 30 illustrates enhanced apoptosis as reflected by increased phosphatidylserine exposure when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation.

25 Figure 31 illustrates enhanced apoptosis as reflected by increased nuclear fragmentation when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation.

Figure 32 illustrates enhanced apoptosis when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation.

30 Figure 33 illustrates down-regulation of Bcl-2 when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation. Figure 33A is the Coomassie-blue-stained protein blot; Figure 33B is the corresponding Western blot.

Figure 34 is a Coomassie-blue-stained protein blot and the corresponding Western blot of COS-7 cells transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the antisense orientation using Bcl-2 as a probe.

5 Figure 35 is a Coomassie-blue-stained protein blot and the corresponding Western blot of COS-7 cells transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation using c-Myc as a probe.

Figure 36 is a Coomassie-blue-stained protein blot and the corresponding Western blot of COS-7 cells transiently transfected with pHM6 containing full-length rat apoptosis-specific eIF-5A in the sense orientation when p53 is used as a probe.

10 Figure 37 is a Coomassie-blue-stained protein blot and the corresponding Western blot of expression of pHM6-full-length rat apoptosis-specific eIF-5A in COS-7 cells using an anti-[HA]-peroxidase probe and a Coomassie-blue-stained protein blot and the corresponding Western blot of expression of pHM6-full-length rat apoptosis-specific eIF-5A in COS-7 cells when a p53 probe is used.

15 Figure 38 is an alignment of human eIF5A2 isolated from RKO cells with the sequence of human eIF5A2 (Genbank accession number XM\_113401).

Figure 39 is a graph depicting the percentage of apoptosis occurring in RKO and RKO-E6 cells following transient transfection. RKO and RKO-E6 cells were transiently transfected with pHM6-LacZ or pHM6-eIF5A1. RKO cells treated with Actinomycin D 20 and transfected with pHM6-eIF5A1 showed a 240% increase in apoptosis relative to cells transfected with pHM6-LacZ that were not treated with Actinomycin D. RKO-E6 cells treated with Actinomycin D and transfected with pHM6-eIF5A1 showed a 105% increase in apoptosis relative to cells transfected with pHM6-LacZ that were not treated with Actinomycin D

25 Figure 40 is a graph depicting the percentage of apoptosis occurring in RKO cells following transient transfection. RKO cells were transiently transfected with pHM6-LacZ, pHM6-eIF5A1, pHM6-eIF5A2, or pHM6-truncated eIF5A1. Cells transfected with pHM6-eIF5A1 showed a 25% increase in apoptosis relative to control cells transfected with pHM6-LacZ. This increase was not apparent for cells transfected with pHM6-eIF5A2 or pHM6-truncated eIF5A1.

Figure 41 is a graph depicting the percentage of apoptosis occurring in RKO cells following transient transfection. RKO cells were either left untransfected or were

transiently transfected with pHM6-LacZ or pHM6-eIF5A1. After correction for transfection efficiency, 60 % of the cells transfected with pHM6-eIF5A1 were apoptotic.

Figure 42 provides the results of a flow cytometry analysis of RKO cell apoptosis following transient transfection. RKO cells were either left untransfected or were 5 transiently transfected with pHM6-LacZ, pHM6-eIF5A1, pHM6-eIF5A2, or pHM6-truncated eIF5A1. The table depicts the percentage of cells undergoing apoptosis calculated based on the area under the peak of each gate. After correction for background apoptosis in untransfected cells and for transfection efficiency, 80% of cells transfected with pHM6-eIF5A1 exhibited apoptosis. Cells transfected with pHM6-LacZ, pHM6-10 eIF5A2 or pHM6-truncated eIF5A1 exhibited only background levels of apoptosis.

Figure 43 provides Western blots of protein extracted from RKO cells treated with 0.25 µg/ml Actinomycin D for 0, 3, 7, 24, and 48 hours. The top panel depicts a Western blot using anti-p53 as the primary antibody. The middle panel depicts a Western blot 15 using anti-eIF5A1 as the primary antibody. The bottom panel depicts the membrane used for the anti-eIF5A1 blot stained with Coomassie blue following chemiluminescent detection to demonstrate equal loading. p53 and eIF5A1 are both upregulated by treatment with Actinomycin D.

Figure 44 is a bar graph showing that both apoptosis-specific eIF-5A (eIF5a) and 20 proliferation eIF-5A (eIF5b) are expressed in heart tissue. The heart tissue was taken from patients receiving coronary artery bypass grafts (CABG). Gene expression levels of eIF5a (light gray bar) are compared to eIF5b (dark gray bar). The X-axis are patient identifier numbers. The Y-axis is pg/ng of 18s (picograms of message RNA over nanograms of 15 ribosomal RNA 18S).

Figure 45 is a bar graph showing that both apoptosis-specific eIF-5A (eIF5a) and 25 proliferation eIF-5A (eIF5b) are expressed in heart tissue. The heart tissue was taken from patients receiving valve replacements. Gene expression levels of eIF5a (light gray bar) are compared to eIF5b (dark gray bar). The X-axis are patient identifier numbers. The Y-axis is pg/ng of 18s (picograms of message RNA over nanograms of ribosomal RNA 18S).

Figure 46 is a bar graph showing the gene expression levels measured by real-time 30 PCR of apoptosis-specific eIF-5A (eIf5a) versus proliferation eIF-5A (eIF5b) in pre-ischemia heart tissue and post ischemia heart tissue. The Y-axis is pg/ng of 18s (picograms of message RNA over nanograms of ribosomal RNA 18S).

Figure 47 depicts schematically an experiment performed on heart tissue. The heart tissue was exposed to normal oxygen levels and the expression levels of apoptosis-specific eIF-5A (eIF5a) and proliferating eIF-5A (eIF5b) measured. Later, the amount of oxygen delivered to the heart tissue was lowered, thus inducing hypoxia and ischemia, and 5 ultimately, a heart attack in the heart tissue. The expression levels of apoptosis-specific eIF-5A (eIF5a) and proliferating eIF-5A (eIF5b) were measured and compared to the expression levels of the heart tissue before it was damaged by ischemia.

Figure 48 shows EKGs of heart tissue before and after the ischemia was induced.

Figure 49 shows the lab bench with the set up of the experiment depicted in Figure

10 47.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention is based, in part, on the discovery and characterization of a full-length cDNA encoding an eIF-5A isolated from rat corpus luteum, which is involved 15 in apoptosis (apoptosis-specific). Therefore, in one embodiment, the present invention provides an isolated nucleic acid comprising a nucleotide sequence encoding a rat apoptosis-specific eIF-5A polypeptide. Also provided by the present invention is a purified polypeptide comprising an amino acid sequence of a rat apoptosis-specific eIF-5A polypeptide. Rat apoptosis-specific eIF-5A polypeptide means any polypeptide specific to 20 rats that is differentially expressed in apoptosing cells and that results from formation of a deoxyhypusine residue by the transfer of the 4-aminobutyl moiety of spermidine to the  $\alpha$ -amino group of a specific conserved lysine of a precursor eIF-5A catalyzed by deoxyhypusine synthase and hydroxylation of this 4-aminobutyl moiety by deoxyhypusine hydroxylase to form hypusine, thereby activating eIF-5A.

25 In addition, the nucleic acid and polypeptide rat apoptosis-specific eIF-5A sequences of the present invention can be used to isolate apoptosis-specific nucleic acids and polypeptides from other cells, tissues, organs, or animals using guidance provided herein and techniques well known to those skilled in the art. The present invention also provides nucleic acid molecules that are suitable as primers or hybridization probes for the 30 detection of nucleic acids encoding a rat apoptosis-specific eIF-5A polypeptide of the invention.

The nucleic acids of the present invention can be DNA, RNA, DNA/RNA duplexes, protein-nucleic acid (PNA), or derivatives thereof. As used herein, a nucleic acid or polypeptide is said to be "isolated" or "purified" when it is substantially free of cellular material or free of chemical precursors or other chemicals. It should be  
5 appreciated that the term isolated or purified does not refer to a library-type preparation containing a myriad of other sequence fragments. The nucleic acid or polypeptide of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the nucleic acid or polypeptide, even if in the presence of  
10 considerable amounts of other components.

The isolated polypeptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. For example recombinant production of proteins involves cloning a nucleic acid molecule encoding either the apoptosis inducing eIF-5A or  
15 DHS into an expression vector. The expression vector is introduced into a host cell and the protein is expressed in the host cell. The protein can then be isolated from the cells by any appropriate purification scheme using standard protein purification techniques.

Preferably, the isolated nucleic acid encoding a rat apoptosis-specific eIF-5A polypeptide of the present invention has a nucleotide sequence of SEQ ID NO:1 and the  
20 purified polypeptide of the present invention has an amino acid sequence of SEQ ID NO:2.

The present inventive rat apoptosis-specific eIF-5A nucleic acids and polypeptides also encompass sequences that have substantial sequence identity or homology to SEQ ID NO:1 and SEQ ID NO:2, respectively, as well as functional derivatives and variants thereof.

25 As used herein, the term "substantial sequence identity" or "substantial homology" is used to indicate that a sequence exhibits substantial structural or functional equivalence with another sequence. Any structural or functional differences between sequences having substantial sequence identity or substantial homology will be *de minimus*; that is, they will not affect the ability of the sequence to function as indicated in the desired application.  
30 Differences may be due to inherent variations in codon usage among different species, for example. Structural differences are considered *de minimus* if there is a significant amount of sequence overlap or similarity between two or more different sequences or if the

different sequences exhibit similar physical characteristics even if the sequences differ in length or structure. Such characteristics include, for example, the ability to hybridize under defined conditions, or in the case of proteins, immunological crossreactivity, similar enzymatic activity, etc. The skilled practitioner can readily determine each of these 5 characteristics by art known methods.

Additionally, two nucleotide sequences are "substantially complementary" if the sequences have at least about 70 percent or greater, more preferably 80 percent or greater, even more preferably about 90 percent or greater, and most preferably about 95 percent or greater sequence similarity between them. Two amino acid sequences are substantially 10 homologous if they have at least 50%, preferably at least 70%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95% similarity between the active, or functionally relevant, portions of the polypeptides.

To determine the percent identity of two sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a 15 second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a 20 position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number 25 of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 30 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular

Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, 5 identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) *J. Mol Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program. BLAST protein searches can be performed with the XBLAST program to obtain 10 amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

The term "functional derivative" of a nucleic acid is used herein to mean a 15 homolog or analog of the gene or nucleotide sequence. A functional derivative may retain at least a portion of the function of the given gene, which permits its utility in accordance with the invention. "Functional derivatives" of the apoptosis-specific eIF-5A polypeptide as described herein are fragments, variants, analogs, or chemical derivatives of apoptosis-specific eIF-5A that retain at least a portion of the apoptosis-specific eIF-5A activity or 20 immunological cross reactivity with an antibody specific for apoptosis-specific eIF-5A. A fragment of the apoptosis-specific eIF-5A polypeptide refers to any subset of the molecule.

Functional variants can also contain substitutions of similar amino acids that result 25 in no change or an insignificant change in function. Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al. (1989) *Science* 244:1081-1085). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as kinase activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding 30 partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al. (1992) *J. Mol. Biol.* 224:899-904; de Vos et al. (1992) *Science* 255:306-312).

A "variant" refers to a molecule substantially similar to either the entire gene or a fragment thereof, such as a nucleotide substitution variant having one or more substituted nucleotides, but which maintains the ability to hybridize with the particular gene or to encode mRNA transcript which hybridizes with the native DNA. A "homolog" refers to a fragment or variant sequence from a different animal genus or species. An "analog" refers to a non-natural molecule substantially similar to or functioning in relation to the entire molecule, a variant or a fragment thereof.

Variant peptides include naturally occurring variants as well as those manufactured by methods well known in the art. Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other proteins based on sequence and/or structural homology to the eIF-5A or DHS proteins of the present invention. The degree of homology/identity present will be based primarily on whether the protein is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

Non-naturally occurring variants of the eIF-5A or DHS proteins of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the proteins. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a protein by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et al., *Science* 247:1306-1310 (1990).

Alternatively, but also preferably, the nucleic acid encoding a rat apoptosis-specific eIF-5A polypeptide of the present invention hybridizes under highly stringent conditions with a nucleotide sequence that is complementary to that of SEQ ID NO:1. The term "hybridization" as used herein is generally used to mean hybridization of nucleic acids at appropriate conditions of stringency as would be readily evident to those skilled in the art

depending upon the nature of the probe sequence and target sequences. Conditions of hybridization and washing are well known in the art, and the adjustment of conditions depending upon the desired stringency by varying incubation time, temperature and/or 5 ionic strength of the solution are readily accomplished. *See, e.g.* Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> edition, Cold Spring Harbour Press, Cold Spring Harbor, New York, 1989.

The choice of conditions is dictated by the length of the sequences being hybridized, in particular, the length of the probe sequence, the relative G-C content of the 10 nucleic acids and the amount of mismatches to be permitted. Low stringency conditions are preferred when partial hybridization between strands that have lesser degrees of complementarity is desired. When perfect or near perfect complementarity is desired, high stringency conditions are preferred. For typical high stringency conditions, the hybridization solution contains 6X S.S.C., 0.01 M EDTA, 1X Denhardt's solution and 0.5% SDS. Hybridization is carried out at about 68°C for about 3 to 4 hours for fragments 15 of cloned DNA and for about 12 to 16 hours for total eucaryotic DNA. For lower stringencies, the temperature of hybridization is reduced to about 42° C below the melting temperature ( $T_m$ ) of the duplex. The  $T_m$  is known to be a function of the G-C content and duplex length as well as the ionic strength of the solution.

As used herein, the phrase "hybridizes to a corresponding portion" of a DNA or 20 RNA molecule means that the molecule that hybridizes, e.g., oligonucleotide, polynucleotide, or any nucleotide sequence (in sense or antisense orientation) recognizes and hybridizes to a sequence in another nucleic acid molecule that is of approximately the same size and has enough sequence similarity thereto to effect hybridization under appropriate conditions. For example, a 100 nucleotide long sense molecule will recognize 25 and hybridize to an approximately 100 nucleotide portion of a nucleotide sequence, so long as there is about 70% or more sequence similarity between the two sequences. It is to be understood that the size of the "corresponding portion" will allow for some mismatches in hybridization such that the "corresponding portion" may be smaller or larger than the molecule which hybridizes to it, for example 20-30% larger or smaller, preferably no more 30 than about 12-15% larger or smaller.

In addition, functional variants of polypeptides can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Amino

acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., *Science* 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological 5 activity or in assays.

For example, an analog of apoptosis-specific eIF-5A refers to a non-natural protein or peptidomimetic substantially similar to either the entire protein or a fragment thereof. Chemical derivatives of apoptosis-specific eIF-5A contain additional chemical moieties not normally a part of the peptide or peptide fragment. Modifications can be introduced 10 into peptide or fragment thereof by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues.

The initial discovery and characterization of a full-length cDNA encoding an apoptosis-specific eIF-5A isolated from rat corpus luteum led to the discovery and 15 characterization of a partial-length cDNA clone encoding a DHS, which is also isolated from rat corpus luteum and involved in apoptosis. Accordingly, in an additional embodiment, the present invention provides an isolated nucleic acid comprising a nucleotide sequence encoding a rat apoptosis-specific DHS polypeptide. Also provided is a purified polypeptide comprising an amino acid sequence of a rat apoptosis-specific DHS 20 polypeptide. Rat apoptosis-specific DHS polypeptide means any suitable polypeptide specific to rats that is differentially expressed in apoptosing cells and that catalyzes formation of a deoxyhypusine residue by the transfer of the 4-aminobutyl moiety of spermidine to the  $\alpha$ -amino group of a specific conserved lysine of inactive eIF-5A to form deoxyhypusine, thereby activating eIF-5A.

25 Preferably, the isolated nucleic acid encoding a rat apoptosis-specific DHS polypeptide of the present invention has a nucleotide sequence of SEQ ID NO:6 and the purified polypeptide of the present invention has an amino acid sequence of SEQ ID NO:7. The present inventive rat apoptosis-specific DHS nucleic acids and polypeptides also encompass sequences that have substantial sequence identity or homology to SEQ ID 30 NO:6 and SEQ ID NO:7, respectively, as well as functional derivatives and variants thereof, which have been described previously. Alternatively, and also preferably, the isolated nucleic acid of the present invention has a nucleotide sequence that hybridizes

under highly stringent conditions with the complement of SEQ ID NO:6, which also has been described previously.

As is the case with the nucleic acids and polypeptides of the rat apoptosis-specific eIF-5A sequences described herein, the nucleic acids and polypeptides of the rat apoptosis-specific DHS sequences of the present invention can be used to isolate apoptosis-specific DHS nucleic acids and polypeptides from other animals, including humans. Isolation of such DHS sequences from animals and human can be achieved using art known methods and guidance provided herein, based on sequence similarities of at least 80% across species. The present invention also provides nucleic acid molecules that are suitable as primers or hybridization probes for the detection of nucleic acids encoding a rat apoptosis-specific DHS polypeptide of the invention.

Apoptosis-specific eIF-5A and DHS are suitable targets for regulation of apoptosis, including apoptosis underlying disease processes, since it likely acts in the post-transcriptional regulation of downstream effectors and transcription factors involved in the apoptotic pathway. Thus, the present invention also provides methods of modulating apoptosis in a cell by administering to the cell an agent that modulates apoptosis-specific eIF-5A and/or DHS function. It should be appreciated by one of skill in the art that the agent can be one that modulates only apoptosis-specific eIF-5A function, only apoptosis-specific DHS function alone, or both apoptosis-specific eIF-5A and DHS function.

Apoptosis can be modulated by any suitable alteration in the normal level of apoptosis-specific eIF-5A and/or DHS function in the cell. As intended herein, modification or alteration can be complete or partial and can include a change in transcriptional or translational control or other change altering apoptosis-specific eIF-5A and/or DHS function in the cell. Apoptosis-specific eIF-5A or DHS function means any activity relating to formation of a deoxyhypusine residue by the transfer of the 4-aminobutyl moiety of spermidine to the  $\alpha$ -amino group of a specific conserved lysine of a precursor eIF-5A, which is catalyzed by DHS, and hydroxylation of this 4-aminobutyl moiety by deoxyhypusine hydroxylase to form hypusine, thereby activating eIF-5A.

In one embodiment of the present invention, the agent can inhibit apoptosis-specific eIF-5A and/or DHS function, thereby inhibiting apoptosis. Inhibiting apoptosis means any decrease, in intensity and/or number, and/or delay in onset of any or all of the

well-defined morphological features characteristic of apoptosis, such as, for example, cell shrinkage, chromatin condensation, nuclear fragmentation, and membrane blebbing.

One agent that can inhibit apoptosis-specific eIF-5A and/or DHS function is an antisense oligonucleotide. Preferably, the antisense oligonucleotide has a nucleotide sequence encoding a portion of an apoptosis-specific eIF-5A polypeptide and/or an apoptosis-specific DHS polypeptide. Many suitable nucleic acid sequences encoding an apoptosis-specific eIF-5A polypeptide and/or DHS polypeptide are known in the art. For example, SEQ ID NOS:1, 3, 4, 5, 11, 15, 19, 20, and 21 (apoptosis-specific eIF-5A nucleic acid sequences), SEQ ID NOS:6 and 8 (apoptosis-specific DHS nucleic acid sequences), SEQ ID NOS:12 and 16 eIF-5A (apoptosis-specific polypeptide sequences), and SEQ ID NO:7 (apoptosis-specific DHS polypeptide sequences), or portions thereof, provide suitable sequences. Others suitable sequences can be found using the known sequences as probes according to the methods described herein.

Accordingly, the present invention also provides antisense oligonucleotides encoding a portion of an apoptosis-specific eIF-5A polypeptide and/or an apoptosis-specific DHS polypeptide, or a complement thereof. The antisense oligonucleotides of the present invention can be in the form of RNA or DNA, e.g., cDNA, genomic DNA, or synthetic RNA or DNA. The DNA can be double-stranded or single stranded, and if single stranded can be the coding strand or non-coding strand. The specific hybridization of an oligomeric compound with its target nucleic acid, resulting in interference with the normal function of the nucleic acid, is generally referred to as "antisense." The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which can be engaged in or facilitated by the RNA. The overall effect of such antisense oligonucleotide is inhibiting of expression of apoptosis-specific eIF-5A and/or DHS and/or the amount of activated apoptosis-specific eIF-5A produced.

Alternatively, the activation of apoptosis-specific eIF-5A by apoptosis-specific DHS can be inhibited by administering chemical agents that inhibit the DHS enzymatic reaction. For example, the onset of DNA laddering reflecting apoptosis is delayed in rat corpus luteum when the animals are treated with spermidine, an inhibitor of the DHS

reaction after induction of apoptosis by injection of PGF-2 $\alpha$  (FIGS. 18-19). Jakus et al., (1993) *J. Biol. Chem.* 268: 13151-13159.

Apoptosis also can be inhibited or substantially decreased by adding agents that degrade apoptosis-specific eIF-5A DNA, RNA, or protein, or that degrade apoptosis-specific DHS DNA, RNA, or protein, thereby preventing the activation of apoptosis-specific eIF-5A by apoptosis-specific DHS. In another embodiment of the invention, inhibition of expression of endogenous mammalian apoptosis-specific DHS, apoptosis-specific eIF-5A, or both, are affected through the use of ribozymes. Examples of suitable drugs include those that inhibit the activation of apoptosis-specific eIF-5A by apoptosis-specific DHS, those that inhibit the activation of apoptosis-specific eIF-5A by deoxyhypusine hydroxylase, those that inhibit transcription and/or translation of apoptosis-specific DHS, those that inhibit transcription and/or translation of apoptosis-specific deoxyhypusine hydroxylase, and those that inhibit transcription or translation of apoptosis-specific eIF-5A. Examples of drugs that inhibit the activation of eIF-5A by apoptosis-specific DHS are spermidine, 1,3-Diamino-propane, 1,4-Diamino-butane (putrescine), 1,7-Diamino-heptane, or 1,8-Diamino-octane.

It is also possible to inhibit apoptosis-specific eIF-5A by inactivating the gene coding for apoptosis-specific eIF-5A in a cell. Such inactivation can occur by deleting the gene in the cell or by introducing a deletion or mutation into the gene and thereby inactivating the gene. The gene can also be inactivated by inserting into the gene another DNA fragment such that expression of the endogenous apoptosis-specific eIF-5A protein does not occur. Likewise, it is possible to inhibit activation of apoptosis-specific eIF-5A by inactivating the gene coding for apoptosis-specific DHS in a cell. Methods for introducing mutations, such as deletions and insertions, into genes in eukaryotic cells are known in the art, e.g., U.S. Patent No. 5,464,764. Oligonucleotides and expression vectors useful for mutation of genes in cells can be made according to methods known in the art and guidance provided herein; for example, methods useful for making and expressing antisense oligonucleotides can be used to make oligonucleotides and expression vectors useful for mutating genes in cells.

It is also possible to inhibit expression of apoptosis-specific eIF-5A by suppressing expression of the gene coding for apoptosis-specific eIF-5A in a cell. Such inactivation can be accomplished via co-suppression, e.g., by introducing nucleotide sequence(s)

coding for apoptosis-specific eIF-5A into a cell such that co-suppression occurs. Likewise, it is possible to inhibit activation of apoptosis-specific eIF-5A by suppressing the expression of the gene coding for apoptosis-specific DHS in a cell via co-suppression. Oligonucleotides and expression vectors useful for co-suppression can be made according 5 to methods known in the art and guidance provided herein; for example, methods useful for making and expressing antisense oligonucleotides can be used to make oligonucleotides and expression vectors useful for co-suppression. Methods for co-suppression are known in the art, e.g., U.S. Patent No. 5,686,649.

One result of the inhibition (through, e.g., antisense, mutation, or co-suppression) 10 is a reduction in the amount of endogenous translatable apoptosis-specific eIF-5A or DHS-encoding mRNA. Consequently, the amount of apoptosis-specific DHS protein produced is reduced, thereby reducing the amount of activated eIF-5A, which in turn reduces translation of apoptosis-specific proteins. Apoptosis is thus inhibited or delayed, since *de novo* protein synthesis is required for the onset of apoptosis.

15 In another embodiment of the present invention, the agent can induce apoptosis-specific eIF-5A or DHS function, thereby inducing apoptosis. Inducing apoptosis means any increase, in intensity or number, or acceleration in onset of any or all of the well-defined morphological features characteristic of apoptosis, such as, for example, cell shrinkage, chromatin condensation, nuclear fragmentation, and membrane blebbing.

20 Any suitable agent that induces apoptosis-specific eIF-5A and/or DHS function can be used. It is appreciated by one of skill in the art that both the inactive and active forms of apoptosis-specific eIF-5A can be administered. If the inactive form, or hypusine-unmodified form, is administered, native apoptosis-specific DHS will activate the eIF-5A. Many suitable nucleic acid sequences encoding an apoptosis-specific eIF-5A polypeptide 25 and/or DHS polypeptide are known in the art. For example, SEQ ID NOS:1, 3, 4, 5, 11, 15, 19, 20, and 21 (apoptosis-specific eIF-5A nucleic acid sequences), SEQ ID NOS:6 and 8 (apoptosis-specific DHS nucleic acid sequences), SEQ ID NOS:12 and 16 eIF-5A (apoptosis-specific polypeptide sequences), and SEQ ID NO:7 (apoptosis-specific DHS polypeptide sequences), or portions thereof, provide suitable sequences. Others suitable 30 sequences can be found using the known sequences as probes according to the methods described herein.

For example, naked nucleic acids (naked DNA vectors such as oligonucleotides or plasmids), or polypeptides, including recombinantly produced polypeptides, can be administered to a cell. Recombinantly produced polypeptides means that the DNA sequences encoding the eIF-5A or the DHS proteins are placed into a suitable expression vector, which is described in detail below. The host is transfected with the expression vector and thereafter produces the desired polypeptides. The polypeptides are then isolated from the host cell. Recombinant apoptosis-inducing eIF-5A protein can be made, for example, in Chinese Hamster Ovary (CHO) cells and activated using recombinant DHS by those skilled in the art. Wang et al. (2001) *J. Biol. Chem.*, 276, 17541-17549; Eriksson et al., (2001) *Semin. Hematol.*, 38, 24-31. The polypeptides can also be synthetic, which are synthesized using known protein synthesis methods.

Polypeptide uptake can be facilitated using ligands, for example, a ligand derived from anthrax that mediates uptake into a broad range of cells. Liu et al. (2001) *J. Biol. Chem.*, 276, 46326-46332. Recombinant protein can also be administered to target cells, tissues, and organs of mammals using liposomes. Liposomes occluding the protein are administered intravenously. Targeting can be achieved by incorporating ligands to specific cell receptors into the liposomes. See, e.g., Kaneda, *Adv Drug Delivery Rev* 43: 197-205 (2000).

One preferred agent that can induce apoptosis-specific eIF-5A or DHS function is an expression vector. Accordingly, the present invention provides expression vectors having a promoter operably linked to a nucleic acid encoding an apoptosis-specific eIF-5A polypeptide and/or DHS polypeptide. The expression vectors of the present invention can be in the form of RNA or DNA, e.g., cDNA, genomic DNA, or synthetic RNA or DNA. The DNA can be double-stranded or single stranded, and if single stranded can be the coding strand or non-coding strand. Any appropriate expression vector (see, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual* (Elsevier, N.Y.: 1985)) can be used. Preferably, the expression vector has a promoter sequence operably linked to a nucleotide sequence encoding an apoptosis-specific (related) eIF-5A polypeptide and/or apoptosis-specific (related) DHS polypeptide.

Within the expression vector, the desired nucleic acid and the promoter are operably linked such that the promoter is able to drive the expression of the nucleic acid. Any suitable promoter can be used provided that the nucleic acid is expressed. Examples

of such suitable promoters include various viral promoters, eucaryotic promoters, and constitutively active promoters. As long as this operable linkage is maintained, the expression vector can include more than one nucleic acid (e.g., nucleic acids encoding both apoptosis-specific eIF-5A and/or DHS). The expression vector can optionally include 5 other elements, such as polyadenylation sequences, ribosome entry sites, transcriptional regulatory elements (e.g., enhancers, silencers, etc.), other sequences for enhancing the stability of the vector or transcript or the translation or processing of the desired transcript within the cells (e.g., secretion signals, leaders, etc.), or any other suitable element.

10 Expression vector can be derived from viruses such as adenovirus, adeno-associated virus, herpesvirus, retrovirus or lentivirus. The expression vector of the present invention can be transfected into host cells, which include, but are not limited to, bacterial species, mammalian or insect host cell systems including baculovirus systems (see, e.g., Luckow et al., *Bio/Technology*, 6, 47 (1988)), and established cell lines such 293, COS-7, C127, 3T3, CHO, HeLa, BHK, etc.

15 Adenoviral vectors are preferred because, unlike plasmids and other viral vectors (e.g., herpes simplex virus), adenoviral vectors achieve gene transfer in both dividing and nondividing cells, with high levels of protein expression in cardiovascular relevant sites such as myocardium, vascular endothelium, and skeletal muscle. Furthermore, the gene transferred by an adenoviral vector functions in an epichromosomal position and thus 20 carries little risk of inappropriately inserting the transferred gene into a critical site of the host genome. The adenoviral vector also desirably is deficient in at least one gene function required for viral replication. Preferably, the adenoviral vector is deficient in at least one essential gene function of the E1, E2, and/or E4 regions of the adenoviral genome. More preferably, the vector additionally is deficient in at least part of the E3 25 region of the adenoviral genome (e.g., an XbaI deletion of the E3 region).

Recombinant adenovirus can be delivered to cultured cells by simply adding the virus to the culture media. Infection of host animals/humans can be achieved by directly injecting the viral particles into the bloodstream or into the desired tissue. The half-life of the virus in serum can be extended by complexing the virus with liposomes (e.g. 30 Lipofectin, Life Technologies) or polyethylene glycol. The adenovirus vector normally enters the cell through an interaction between the knob domain of the viral fiber protein and the coxsackievirus and adenovirus receptor, CAR. The viral vector can be directed to

specific cells, or to cells which do not express the CAR, by genetically engineering the virus to express a ligand specific to a certain cell receptor.

In an alternate embodiment, apoptosis can be initiated or enhanced by chemically upregulating the transcription of endogenous apoptosis-specific eIF-5A, or apoptosis-specific DHS, or both, with chemicals, or by chemically enhancing the activation of apoptosis-specific eIF-5A. In one such embodiment, PGF-2 $\alpha$  is administered to the cancer cells or tumor of the animal/human to upregulate the transcription of DHS and eIF-5A.

Apoptosis-specific eIF-5A is a suitable target for regulation of apoptosis, including apoptosis underlying disease processes, since it likely acts in the post-transcriptional regulation of downstream effectors and transcription factors involved in the apoptotic pathway. The present inventive methods of modulating apoptosis-specific eIF-5A and apoptosis-specific DHS, either alone or in combination, can be accomplished in cells of animals resulting in induction or enhancement of apoptosis and giving rise to novel methods and compositions for the treatment and prevention of diseases caused by, causing, or otherwise having an etiology associated with an inability of cells to undergo apoptosis.

Many important human diseases are caused by abnormalities in the control of apoptosis. These abnormalities can result in either a pathological increase in cell number (e.g. cancer) or a damaging loss of cells (e.g. degenerative diseases). As non-limiting examples, the methods and compositions of the present invention can be used to prevent or treat the following apoptosis-associated diseases and disorders: neurological/neurodegenerative disorders (e.g., Alzheimer's, Parkinson's, Huntington's, Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease), autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis), Duchenne Muscular Dystrophy (DMD), motor neuron disorders, ischemia, heart ischemia, chronic heart failure, stroke, 25 infantile spinal muscular atrophy, cardiac arrest, renal failure, atopic dermatitis, sepsis and septic shock, AIDS, hepatitis, glaucoma, diabetes (type 1 and type 2), asthma, retinitis pigmentosa, osteoporosis, xenograft rejection, and burn injury.

The present inventive methods can be used for therapeutic treatments to an animal having a cancerous cell or suffering from a tumor in an amount sufficient to kill the 30 cancerous cell or inhibit the progression of the tumor, respectively. An amount adequate to accomplish this is defined as a therapeutically effective dose. Amounts effective for

this use will depend upon the severity of the disease and the general state of the animal's own immune system.

Inhibition of tumor growth means prevention or reduction of the progression of the tumor, e.g., the growth, invasiveness, metastases and/or recurrence of the tumor. The 5 present inventive methods can be used to treat any suitable tumor, including, for example, tumors of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix or liver. Animals, preferably mammals, and more preferably humans can be treated using the compositions and methods of the present invention. The present 10 inventive methods can thus be carried out *in vitro*, *ex vivo*, or *in vivo*.

Dosing schedules will also vary with the disease state and status of the animal, and will typically range from a single bolus dosage or continuous infusion to multiple 15 administrations per day (e.g., every 4-6 hours), or as indicated by the treatment and the animal's condition. It should be noted, however, that the present invention is not limited to any particular dose.

In the present invention, any suitable method or route can be used for administration, for example, oral, intravenous, intraperitoneal, subcutaneous, or 20 intramuscular administration. The dose of antagonist administered depends on numerous factors, including, for example, the type of molecule administered, the type and severity tumor being treated and the route of administration. It should be emphasized, however, 15 that the present invention is not limited to any particular method or route of administration.

In one alternative embodiment, the present inventive methods can be used in combination with one or more traditional therapies. For example, a suitable antineoplastic agent can be used, such as a chemotherapeutic agent or radiation. In an additional 25 alternative embodiment, the present inventive methods can be used in combination with one or more suitable adjuvants, such as, for example, cytokines (IL-10 and IL-13, for example) or other immune stimulators.

In another alternative embodiment, diagnosis of an apoptosis-related or associated disorder (such as ischemia of the heart tissue) can be made by measuring the expression 30 levels of apoptosis-specific eIF-5A and proliferating eIF-5A (eIF-5b). The proliferating eIF-5A (eIF-5b) and the apoptosis-specific eIF-5A differ in that they are transcribed from different locations by different promoters; although the two are structurally homologous,

with differences in the carboxy terminus. The method of diagnosis of the present invention involves comparing the amount of proliferating eIF-5A present in a given cell with the amount of apoptosis-specific eIF-5A present in the same cell. The levels of gene expression are measured for both proliferating eIF-5A and apoptosis-specific eIF-5A and 5 compared to each other. During normal functioning, a cell will have either the same amount or greater amount of proliferating eIF-5A (also referred to herein as eIF-5A2) than apoptosis-specific eIF-5A (also referred to herein as eIF-5A1). However, in cells undergoing death or stress such as ischemia, the apoptosis-specific eIF-5A is expressed at a greater level than the proliferating eIF-5A. Thus, detecting the increased levels of 10 expression of apoptosis-specific eIF-5A, provides for method of identifying or diagnosing an apoptosis-related or associated disorder (such as ischemia).

Figure 46 shows the results of an experiment where levels of apoptosis-specific eIF-5a (eIF5a) and proliferating eIF-5A (eIF5b) were measured before and after ischemia in heart tissue was induced. See also example 6. Before ischemia, the expression levels of 15 apoptosis-specific eIF-5a (eIF5a) and proliferating eIF-5A (eIF5b) were roughly similar and were at low levels. After ischemia was induced, the level of apoptosis-specific eIF-5a (eIF5a) increases much more than the level of proliferating eIF-5A (eIF5b).

Knowing that the levels of expression of apoptosis-specific eIF-5a (eIF5a) and proliferating eIF-5A (eIF5b) are at relative low levels and are in relative balance with 20 respect to each other in normal tissues, monitoring and detecting an increase in the gene expression level of apoptosis-specific eIF-5a (eIF5a) provides a method of diagnosing various diseases or conditions that place the cells or tissue in stress, such as ischemia.

Further, by being able to detect these conditions by measuring the levels of gene expression, there is provided methods of treating such conditions. For example, if 25 ischemia is detected in the heart by either methods known in the art or by detecting an increase in levels of apoptosis-specific eIF-5a (eIF5a) gene expression, agents that would inhibit or decrease the levels of gene expression may be provided and thus decrease the incidence of cell death.

The agents that inhibit or decrease levels of gene expression of apoptosis-specific 30 eIF-5a (eIF5a) are discussed herein above, including the use of antisense oligonucleotides to the apoptosis-specific eIF-5a (eIF5a). A preferred antisense oligonucleotide comprises an oligonucleotide complementary to the coding strand of a nucleotide sequence encoding

an apoptosis-specific eIF-5a, such as but not limited to, the nucleotide sequences listed as SEQ ID NO: 3 or 4.

In some cancer cells, the normal regulatory mechanisms go awry and the amount of apoptosis-specific eIF-5A relative to the amount of proliferating eIF-5A is altered (the 5 levels of apoptosis-specific eIF-5A increase such that they are greater than the proliferating eIF-5A). This potentially allows for diagnosis of a cell as cancerous prior to any phenotypic changes in the cell.

In addition, in ischemic heart tissue, the amount of apoptosis-specific eIF-5A relative to the amount of proliferating eIF-5A is altered so that the levels of apoptosis-10 specific eIF-5A are increased relative to the amount of proliferating eIF-5A.

In yet another embodiment, the ratio of proliferating eIF-5A to apoptosis-specific eIF-5A can be used in drug screening. Such a method also involves comparing the amount of proliferating eIF-5A present in a given cell with the amount of apoptosis-specific eIF-5A present in the same cell. The normal ratio of proliferating eIF-5A to apoptosis-specific 15 eIF-5A would be compared to the ratio of proliferating eIF-5A to apoptosis-specific eIF-5A after contacting the cell with the drug candidate. Alterations in the ratio of proliferating eIF-5A to apoptosis-specific eIF-5A after contact allows for identification of those candidates that have apoptosis-modulating activity. Candidates having apoptosis-modulating activity can be useful in treating diseases associated with apoptosis, either 20 through inhibition or induction of apoptosis. In addition, alterations in the ratio of proliferating eIF-5A to apoptosis-specific eIF-5A can be used to modulate apoptosis, which may also be useful to treat any of the conditions described herein as relating to abnormal apoptosis.

Using this method a large number of potential candidates, i.e., a library can be 25 effectively screened to identify members of the library that modulate apoptosis. Any candidate or library of candidates can be screened using this method. For example, biological response modifiers that have shown promise as apoptosis modulators, including monoclonal antibodies that alter signal transduction pathways, cytokines such as TRAIL (Apo2 ligand), ligands for retinoid/steroid family nuclear receptors, and small-molecule 30 compounds that bind and inhibit protein kinases, can be screened for definite apoptosis-modulating activity using the present methods.

One suitable candidate is a protein kinase C-alpha antisense oligonucleotide, ISIS 3521 (ISIS Pharmaceuticals, Inc., Carlsbad, CA), which has anti-tumor activity. Other specific candidates include caspases (Idun Pharmaceuticals, San Diego, CA), which are known to play a crucial role in the triggering and execution of apoptosis in a variety of cell types leading to cancer and neurodegenerative diseases; GENASENSE™ (Genta, Inc., Berkeley Heights, NJ), which is an antisense drug that blocks the production of Bcl-2; INGN 241 (Introgen Therapeutics, Inc., Houston, TX), which is a gene therapy targeting P53; rituximab (IDEC Corporation, Osaka, Japan), which is an anti-CD20 monoclonal antibody; and general apoptosis driven therapies for cardiovascular disease and cancer (Ægera Therapeutics Inc., Quebec, Canada).

It is understood that the nucleic acids and polypeptides of the present invention, where used in an animal for the purpose of prophylaxis or treatment, will be administered in the form of a composition additionally comprising a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers can further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the binding proteins. The compositions of the injection can, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the mammal.

The compositions of this invention can be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions, dispersions or suspensions, liposomes, suppositories, injectable and infusible solutions. The preferred form depends on the intended mode of administration and therapeutic application.

Such compositions can be prepared in a manner well known in the pharmaceutical art. In making the composition the active ingredient will usually be mixed with a carrier, or diluted by a carrier, and/or enclosed within a carrier which can, for example, be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, excipient or medium for the active ingredient. Thus, the composition can be in the form of tablets, lozenges,

sachets, cachets, elixirs, suspensions, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, injection solutions, suspensions, sterile packaged powders and as a topical patch.

5 Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration. The Examples are set forth to aid in understanding the invention but are not intended to, and should not be construed to, limit its scope in any way. The examples do not include detailed descriptions of conventional methods. Such methods are well known  
10 to those of ordinary skill in the art and are described in numerous publications. Detailed descriptions of conventional methods, such as those employed in the construction of vectors and plasmids, the insertion of nucleic acids encoding polypeptides into such vectors and plasmids, the introduction of plasmids into host cells, and the expression and determination thereof of genes and gene products can be obtained from numerous  
15 publication, including Sambrook, J. et al., (1989) Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., Cold Spring Harbor Laboratory Press. All references mentioned herein are incorporated in their entirety.

## EXAMPLES

### 20 EXAMPLE 1

The present example demonstrates isolation and characterization of a full-length cDNA encoding a rat eIF-5A nucleic acid exhibiting apoptosis-specific expression.

#### *Superovulation and Induction of Apoptosis in Rat Corpus Luteum*

25 Immature (21-30 day old) female rats were superovulated by subcutaneous injection with 50 IU of PMSG (Pregnant Mare Serum Gonadotropin) and 60 to 65 hours later with 50 IU of HCG (Human Chorionic Gonadotropin). Seven days after the treatment with HCG, corpus luteum apoptosis was induced by subcutaneous injection with 500 mg of PGF-2 $\alpha$ . Rats were sacrificed at various times (e.g., 1, 8, and 24 hours) after  
30 PGF-2 $\alpha$  treatment, and the corpora lutea were removed and placed in liquid nitrogen.

Control corpus luteum tissue was obtained by sacrificing rats immediately before PGF-2 $\alpha$  treatment.

*Dispersion of Rat Ovarian Corpus Luteum Cells*

5 Six to nine days after superovulation, rats were treated by multisite subcutaneous injection with 500 mg PGF-2 $\alpha$ . Fifteen to thirty minutes later, the ovaries were removed from the superovulated rats, placed in EBSS (Gibco) on ice, blotted dry and weighed. Connective tissue was trimmed away, and the ovaries were minced finely with a razor blade and washed twice with EBSS 2X. Collagenase solution was prepared by vortexing 10 6.5 mg of collagenase (Sigma, Catalogue # C 5138) in 5ml of EBSS. Minced tissue from 8 ovaries was added to 5 ml of collagenase in EBSS in a 50 ml Erlenmeyer flask and agitated gently by withdrawing several times into a Diamed pipette. The flask with minced tissue was then placed in a water bath at 37° C for 20 minutes with gentle shaking (Position 45 on GFL incubator) under 95% air, 5% CO<sub>2</sub>.

15 Following this incubation, the flask was placed on ice, and the suspension of cells was transferred with a plastic transfer pipet onto a Nitex filter fitted with Swiss Nitex Nylon Monofilament (75 m). The filtrate was collected into a 15 ml Falcon test tube. A second aliquot (2.5 ml) of collagenase solution (6.5 mg collagenase/5ml EBSS) was added to the minced tissue remaining in the 50 ml Erlenmeyer flask, agitated gently using a 20 pipette, incubated for 10 minutes and filtered as above. The two filtrates were combined and centrifuged in a clinical centrifuge (~200g) for 5 minutes at room temperature. All but ~2ml of the supernatant were removed with a pipet and discarded, and the sedimented cells were resuspended in the remaining 2 ml of supernatant.

25 The cells were washed twice by adding 5 ml of MEM and centrifuging and resuspending as above. The washed cells were resuspended in 30 mls of MEM containing 10 mm glutamine in a 50 ml Erlenmeyer flask and incubated for 1 hour without shaking at 37° C under 95% air, 5% CO<sub>2</sub>. The cells were then sedimented by centrifugation as above and resuspended in MEM containing 10 mM glutamine.

30 The concentration of dispersed cells was determined using a hemocytometer, and viability was assessed using trypan blue dye. Aliquots of 2-5 x10<sup>5</sup> cells were placed in 12x75 mm test tubes and incubated without shaking for 2-5 hours at 37° C under 95 % air,

5 % CO<sub>2</sub>. The progress of apoptosis during this period was monitored by assessing the degree of DNA laddering.

*Visualization of Apoptosis in Rat Corpus Luteum by DNA Laddering*

5 The degree of apoptosis was determined by DNA laddering. Genomic DNA was isolated from dispersed corpus luteal cells or from excised corpus luteum tissue using the QIAamp DNA Blood Kit (Qiagen) according to the manufacturer's instructions. Corpus luteum tissue was excised before the induction of apoptosis by treatment with PGF-2 $\alpha$ , 1 and 24 hours after induction of apoptosis. The isolated DNA was end-labeled by  
10 incubating 500 ng of DNA with 0.2  $\mu$ Ci [ $\alpha$ -<sup>32</sup>P]dCTP, 1 mM Tris, 0.5 mM EDTA, 3 units of Klenow enzyme, and 0.2 pM each of dATP, dGTP, and dTTP at room temperature for 30 minutes. Unincorporated nucleotides were removed by passing the sample through a 1 ml Sepadex G-50 column according to Sambrook et al. The samples were then resolved by Tris-acetate-EDTA (1.8 %) gel electrophoresis. The gel was dried for 30 minutes at  
15 room temperature under vacuum and exposed to x-ray film at - 80° C for 24 hours.

20 In one experiment, the degree of apoptosis in superovulated rat corpus lutea was examined either 0, 1, or 24 hours after injection with PGF-2 $\alpha$ . In the 0 hour control, the ovaries were removed without PGF-2 $\alpha$  injection. Laddering of low molecular weight DNA fragments reflecting nuclease activity associated with apoptosis is not evident in control corpus luteum tissue excised before treatment with PGF-2 $\alpha$ , but is discernible within 1 hour after induction of apoptosis and is pronounced by 24 hours after induction of apoptosis, which is shown in FIG. 16. In this figure, the top panel is an autoradiograph of the Northern blot probed with the <sup>32</sup>P-dCTP-labeled 3'-untranslated region of rat corpus luteum apoptosis-specific DHS cDNA. The lower panel is the ethidium bromide stained  
25 gel of total RNA. Each lane contains 10  $\mu$ g RNA. The data indicate that there is down-regulation of eIF-5A transcript following serum withdrawal.

30 In another experiment, the corresponding control animals were treated with saline instead of PGF-2 $\alpha$ . Fifteen minutes after treatment with saline or PGF-2 $\alpha$ , corpora lutea were removed from the animals. Genomic DNA was isolated from the corpora lutea at 3 hours and 6 hours after removal of the tissue from the animals. DNA laddering and increased end labeling of genomic DNA are evident 6 hours after removal of the tissue from the PGF-2 $\alpha$ -treated animals, but not at 3 hours after removal of the tissue. See FIG.

17. DNA laddering reflecting apoptosis is also evident when corpora lutea are excised 15 minutes after treatment with PGF-2 $\alpha$  and maintained for 6 hours under *in vitro* conditions in EBSS (Gibco). Nuclease activity associated with apoptosis is also evident from more extensive end labeling of genomic DNA.

5 In another experiment, superovulation was induced by subcutaneous injection with 500  $\mu$ g of PGF-2 $\alpha$ . Control rats were treated with an equivalent volume of saline solution. Fifteen to thirty minutes later, the ovaries were removed and minced with collagenase. The dispersed cells from rats treated with PGF-2 $\alpha$  were incubated in 10 mm glutamine + 10 mm spermidine for 1 hour and for a further 5 hours in 10 mm glutamine without 10 spermidine (lane 2) or in 10 mm glutamine + 10 mm spermidine for 1 hour and for a further 5 hours in 10 mm glutamine + 1 mm spermidine (lane 3). Control cells from rats treated with saline were dispersed with collagenase and incubated for 1 hour and a further 5 hours in glutamine only (lane 1). Five hundred nanograms of DNA from each sample was labeled with [ $\alpha$ -<sup>32</sup>P]-dCTP using klenow enzyme, separated on a 1.8 % agarose gel, 15 and exposed to film for 24 hours. Results are shown in FIG. 18.

In yet another experiment, superovulated rats were injected subcutaneously with 1 mg/100 g body weight of spermidine, delivered in three equal doses of 0.333 mg/100 g body weight, 24, 12, and 2 hours prior to a subcutaneous injection with 500  $\mu$ g PGF-2 $\alpha$ . Control rats were divided into three sets: no injections, three injections of spermidine but 20 no PGF-2 $\alpha$ ; and three injections with an equivalent volume of saline prior to PGF-2 $\alpha$  treatment. Ovaries were removed front the rats either 1 hour and 35 minutes or 3 hours and 45 minutes after prostaglandin treatment and used for the isolation of DNA. Five hundred nanograms of DNA from each sample was labeled with [ $\alpha$ -<sup>32</sup>P]-dCTP using Klenow enzyme, separated on a 1.8 % agarose gel, and exposed to film for 24 hours: lane 25 1, no injections (animals were sacrificed at the same time as for lanes 3-5); lane 2, three injections with spermidine (animals were sacrificed at the same time as for lanes 3-5); lane 3, three injections with saline followed by injection with PGF-2 $\alpha$  (animals were sacrificed 1 h and 35 min after treatment with PGF-2 $\alpha$ ); lane 4, three injections with spermidine followed by injection with PGF-2 $\alpha$  (animals were sacrificed 1 h and 35 min after treatment with PGF-2 $\alpha$ ); lane 5, three injections with spermidine followed by injection with PGF-2 $\alpha$  (animals were sacrificed 1 h and 35 min after treatment with PGF-2 $\alpha$ ); lane 6, three 30 injections with spermidine followed by injection with PGF-2 $\alpha$  (animals were sacrificed 3 h

and 45 min after treatment with PGF-2 $\alpha$ ); lane 7, three injections with spermidine followed by injection with PGF-2 $\alpha$  (animals were sacrificed 3 h and 45 min after treatment with PGF-2 $\alpha$ ). Results are shown in FIG. 19.

5

### *RNA Isolation*

Total RNA was isolated from corpus luteum tissue removed from rats at various times after PGF-2 $\alpha$  induction of apoptosis. Briefly, the tissue (5 g) was ground in liquid nitrogen. The ground powder was mixed with 30 ml guanidinium buffer (4 M guanidinium isothiocyanate, 2.5 mM NaOAc pH 8.5, 0.8%  $\beta$ -mercaptoethanol). The mixture was filtered through four layers of Miracloth and centrifuged at 10,000g at 4° C for 30 minutes. The supernatant was then subjected to cesium chloride density gradient centrifugation at 11,200g for 20 hours. The pelleted RNA was rinsed with 75% ethanol, resuspended in 600 ml DEPC-treated water and the RNA precipitated at -70° C with 1.5 ml 95% ethanol and 60 ml of 3M NaOAc.

15

### *Genomic DNA Isolation and Laddering*

Genomic DNA was isolated from extracted corpus luteum tissue or dispersed corpus luteal cells using the QIAamp DNA Blood Kit (Qiagen) according to the manufacturer's instructions. The DNA was end-labeled by incubating 500 ng of DNA with 20 0.2  $\mu$ Ci [ $\alpha$ -<sup>32</sup>P]dCTP, 1 mM Tris, 0.5 mM EDTA, 3 units of Klenow enzyme, and 0.2 pM each of dATP, dGTP, and dTTP, at room temperature for 30 minutes. Unincorporated nucleotides were removed by passing the sample through a 1-ml Sephadex G-50 column according to the method described by Maniatis et al. The samples were then resolved by Tris-acetate-EDTA (2 %) gel electrophoresis. The gel was dried for 30 minutes at room 25 temperature under vacuum and exposed to x-ray film at - 80° C for 24 hours.

### *Plasmid DNA Isolation, DNA Sequencing*

The alkaline lysis method described by Sambrook et al., *supra*, was used to isolate plasmid DNA. The full-length positive cDNA clone was sequenced using the dideoxy 30 sequencing method. Sanger et al., Proc. Natl. Acad. Sci. USA, 74:5463-5467. The open reading frame was compiled and analyzed using BLAST search (GenBank, Bethesda, MD) and sequence alignment was achieved using a BCM Search Launcher: Multiple Sequence

Alignments Pattern-Induced Multiple Alignment Method (see F. Corpet, Nuc. Acids Res., 16:10881-10890, (1987). Sequences and sequence alignments are shown in FIGS. 5-11.

*Northern Blot Hybridization of Rat Corpus Luteum RNA*

5 Twenty milligrams of total RNA isolated from rat corpus luteum at various stages of apoptosis were separated on 1% denatured formaldehyde agarose gels and immobilized on nylon membranes. The full-length rat apoptosis-specific eIF-5A cDNA (SEQ ID NO:1) labeled with  $^{32}\text{P}$ -dCTP using a random primer kit (Boehringer) was used to probe the membranes  $7 \times 10^7$ . Alternatively, full length rat apoptosis-specific DHS cDNA (SEQ ID 10 NO:6) labeled with  $^{32}\text{P}$ -dCTP using a random primer kit (Boehringer) was used to probe the membranes ( $7 \times 10^7$  cpm). The membranes were washed once with 1x SSC, 0.1% SDS at room temperature and three times with 0.2x SSC, 0.1% SDS at 65° C. The membranes were dried and exposed to X-ray film overnight at -70° C.

15 As can be seen, eIF-5A and DHS are both upregulated in apoptosing corpus luteum tissue. Expression of apoptosis-specific eIF-5A is significantly enhanced after induction of apoptosis by treatment with PGF-2 $\alpha$  – low at time zero, increased substantially within 1 hour of treatment, increased still more within 8 hours of treatment and increased slightly within 24 hours of treatment (FIG. 14). Expression of DHS was low at time zero, increased substantially within 1 hour of treatment, increased still more within 8 hours of 20 treatment and increased again slightly within 24 hours of treatment (FIG. 15).

*Generation of an Apoptosing Rat Corpus Luteum RT-PCR*

*Product Using Primers Based on Yeast, Fungal and Human*

*eIF-5A Sequences*

25 A partial-length apoptosis-specific eIF-5A sequence (SEQ ID NO:11) corresponding to the 3' end of the gene was generated from apoptosing rat corpus luteum RNA template by RT-PCR using a pair of oligonucleotide primers designed from yeast, fungal and human eIF-5A sequences. The upstream primer used to isolate the 3'end of the rat eIF-5A gene is a 20 nucleotide degenerate primer: 5' TCSAARACHGGNAAGCAYGG 30 3' (SEQ ID NO:9), wherein S is selected from C and G; R is selected from A and G; H is selected from A, T, and C; Y is selected from C and T; and N is any nucleic acid. The downstream primer used to isolate the 3'end of the rat eIF-5A gene contains 42

nucleotides: 5' GCGAAGCTTCCATGG CTCGAGTTTTTTTTTTTTTTTT 3' (SEQ ID NO:10). A reverse transcriptase polymerase chain reaction (RT-PCR) was carried out. Briefly, using 5 mg of the downstream primer, a first strand of cDNA was synthesized. The first strand was then used as a template in a RT-PCR using both the 5 upstream and downstream primers.

Separation of the RT-PCR products on an agarose gel revealed the presence a 900 bp fragment, which was subcloned into pBluescript<sup>TM</sup> (Stratagene Cloning Systems, LaJolla, CA) using blunt end ligation and sequenced (SEQ ID NO:11). The cDNA sequence of the 3' end is SEQ ID NO:11 and the amino acid sequence of the 3' end is SEQ 10 ID NO:12. *See FIGS. 1-2.*

A partial-length apoptosis-specific eIF-5A sequence (SEQ ID NO:15) corresponding to the 5' end of the gene and overlapping with the 3' end was generated from apoptosing rat corpus luteum RNA template by RT-PCR. The 5' primer is a 24-mer having the sequence, 5' CAGGTCTAGAGTTGGAATCGAAGC 3' (SEQ ID NO:13), that 15 was designed from human eIF-5A sequences. The 3' primer is a 30-mer having the sequence, 5' ATATCTCGAGCCTT GATTGCAACAGCTGCC 3' (SEQ ID NO:14) that was designed according to the 3' end RT-PCR fragment. A reverse transcriptase-polymerase chain reaction (RT-PCR) was carried out. Briefly, using 5 mg of the downstream primer, a first strand of cDNA was synthesized. The first strand was then 20 used as a template in a RT-PCR using both the upstream and downstream primers.

Separation of the RT-PCR products on an agarose gel revealed the presence a 500 bp fragment, which was subcloned into pBluescript<sup>TM</sup> (Stratagene Cloning Systems, LaJolla, CA) using XbaI and XhoI cloning sites present in the upstream and downstream primers, respectively, and sequenced (SEQ ID NO:15). The cDNA sequence of the 5' end 25 is SEQ ID NO:15, and the amino acid sequence of the 5' end is SEQ ID NO:16. *See FIG. 2.*

The sequences of the 3' and 5' ends of the rat apoptosis-specific eIF-5A (SEQ ID NO:11 and SEQ ID NO:15, respectively) overlapped and gave rise to the full-length cDNA sequence (SEQ ID NO:1). This full-length sequence was aligned and compared with 30 sequences in the GeneBank data base. *See FIGS. 1-3.* The cDNA clone encodes a 154 amino acid polypeptide (SEQ ID NO:2) having a calculated molecular mass of 16.8 KDa. The nucleotide sequence, SEQ ID NO:1, for the full length cDNA of the rat apoptosis-

specific corpus luteum eIF-5A gene obtained by RT-PCR is depicted in FIG. 3 and the corresponding derived amino acid sequence is SEQ ID NO:2. The derived full-length amino acid sequence of eIF-5A was aligned with human and mouse eIF-5a sequences. See FIG. 8-10.

5

*Generation of an Apoptosing Rat Corpus Luteum RT-PCR*

*Product Using Primers Based on a Human DHS Sequence*

A partial-length apoptosis-specific DHS sequence (SEQ ID NO:6) corresponding to the 3' end of the gene was generated from apoptosing rat corpus luteum RNA template 10 by RT-PCR using a pair of oligonucleotide primers designed from a human DHS sequence. The 5' primer is a 20-mer having the sequence, 5'  
GTCTGTATTATTGGGCC 3' (SEQ ID NO. 17); the 3' primer is a 42-mer having the sequence, 5' GCGAAGCTTCCATGGC TCGAGTTTTTTTTTTTTTT 3' (SEQ ID NO:18). A reverse transcriptase polymerase chain reaction (RT-PCR) was carried out.  
15 Briefly, using 5 mg of the downstream primer, a first strand of cDNA was synthesized. The first strand was then used as a template in a RT-PCR using both the upstream and downstream primers.

Separation of the RT-PCR products on an agarose gel revealed the presence a 606 bp fragment, which was subcloned into pBluescript<sup>TM</sup> (Stratagene Cloning Systems, 20 LaJolla, CA) using blunt end ligation and sequenced (SEQ ID NO:6). The nucleotide sequence (SEQ ID NO:6) for the partial length cDNA of the rat apoptosis-specific corpus luteum DHS gene obtained by RT-PCR is depicted in FIG. 4 and the corresponding derived amino acid sequence is SEQ ID NO.7.

25 *Isolation of Genomic DNA and Southern Analysis*

Genomic DNA for southern blotting was isolated from excised rat ovaries. Approximately 100 mg of ovary tissue was divided into small pieces and placed into a 15 ml tube. The tissue was washed twice with 1 ml of PBS by gently shaking the tissue suspension and then removing the PBS using a pipette. The tissue was resuspended in 30 2.06 ml of DNA-buffer (0.2 M Tris-HCl pH 8.0 and 0.1 mM EDTA) and 240  $\mu$ l of 10 % SDS and 100  $\mu$ l of proteinase K (Boehringer Manheim; 10 mg/ml) was added. The tissue was placed in a shaking water bath at 45° C overnight. The following day another 100  $\mu$ l

of proteinase K (10 mg/ml) was added and the tissue suspension was incubated in a water-bath at 45 °C for an additional 4 hours. After the incubation the tissue suspension was extracted once with an equal volume of phenol:chloroform:iso-amyl alcohol (25:24:1) and once with an equal volume of chloroform:iso-amyl alcohol (24:1). Following the 5 extractions 1/10th volume of 3M sodium acetate (pH 5.2) and 2 volumes of ethanol were added. A glass pipette sealed and formed into a hook using a Bunsen burner was used to pull the DNA threads out of solution and to transfer the DNA into a clean microcentrifuge tube. The DNA was washed once in 70 % ethanol and air-dried for 10 minutes. The DNA 10 pellet was dissolved in 500 µl of 10 mM Tris-HCl (pH 8.0), 10 µl of RNase A (10 mg/ml) was added, and the DNA was incubated for 1 hour at 37 °C. The DNA was extracted once with phenol:chloroform:iso-amyl alcohol (25:24:1) and the DNA was precipitated by adding 1/10th volume of 3 M sodium acetate (pH 5.2) and 2 volumes of ethanol. The DNA was pelleted by centrifugation for 10 minutes at 13,000 x g at 4° C. The DNA pellet 15 was washed once in 70 % ethanol and dissolved in 200 µl 10 mM Tris-HCl (pH 8.0) by rotating the DNA at 4 °C overnight.

For Southern blot analysis, genomic DNA isolated from rat ovaries was digested with various restriction enzymes that either do not cut in the endogenous gene or cut only once. To achieve this, 10 µg genomic DNA, 20 µl 10X reaction buffer and 100 U restriction enzyme were reacted for five to six hours in a total reaction volume of 200 µl. 20 Digested DNA was loaded onto a 0.7 % agarose gel and subjected to electrophoresis for 6 hours at 40 volts or overnight at 15 volts. After electrophoresis, the gel was depurinated for 10 minutes in 0.2 N HCl followed by two 15-minute washes in denaturing solution (0.5 M NaOH, 1.5 M NaCl) and two 15 minute washes in neutralizing buffer (1.5 M NaCl, 0.5 M Tris-HCl pH 7.4). The DNA was transferred to a nylon membrane, and the membrane 25 was prehybridized in hybridization solution (40 % formamide, 6 X SSC, 5 X Denhart's, solution (1 X Denhart's solution is 0.02 % Ficoll, 0.02 % PVP, and 0.02 % BSA), 0.5 % SDS, and 1.5 mg of denatured salmon sperm DNA). A 700 bp PCR fragment of the 3' UTR of rat eIF-5A cDNA (650 bp of 3' UTR and 50 bp of coding) was labeled with [ $\alpha$ -<sup>32</sup>P]-dCTP by random priming and added to the membrane at 1 X 10<sup>6</sup> cpm/ml.

30 Similarly, a 606 bp PCR fragment of the rat DHS cDNA (450 bp coding and 156 bp 3' UTR) was random prime labeled with [ $\alpha$ -<sup>32</sup>P]-dCTP and added at 1 X 10<sup>6</sup> cpm/ml to a second identical membrane. The blots were hybridized overnight at 42° C and then

washed twice with 2 X SSC and 0.1 % SDS at 42° C and twice with 1 X SSC and 0.1 % SDS at 42° C. The blots were then exposed to film for 3-10 days.

Rat corpus genomic DNA was cut with restriction enzymes as indicated on FIG. 20 and probed with <sup>32</sup>P-dCTP-labeled full-length eIF-5A cDNA. Hybridization under high 5 stringency conditions revealed hybridization of the full-length cDNA probe to several restriction fragments for each restriction enzyme digested DNA sample, indicating the presence of several isoforms of eIF-5A. Of particular note, when rat genomic DNA was digested with EcoRV, which has a restriction site within the open reading frame of apoptosis-specific eIF-5A, two restriction fragments of the apoptosis-specific isoform of 10 eIF-5A were detectable in the Southern blot. The two fragments are indicated with double arrows in FIG. 20. The restriction fragment corresponding to the apoptosis-specific isoform of eIF-5A is indicated by a single arrow in the lanes labeled EcoR1 and BamH1, restriction enzymes for which there are no cut sites within the open reading frame. These 15 results suggest that the apoptosis-specific eIF-5A is a single copy gene in rat. As shown in FIGS. 5 through 13, the eIF-5A gene is highly conserved across species, and so it would be expected that there is a significant amount of conservation between isoforms within any species.

Figure 21 shows a Southern blot of rat genomic DNA probed with <sup>32</sup>P-dCTP-labeled partial-length rat corpus luteum apoptosis-specific DHS cDNA. The genomic 20 DNA was cut with EcoRV, a restriction enzyme that does not cut the partial-length cDNA used as a probe. Two restriction fragments are evident indicating that there are two copies of the gene or that the gene contains an intron with an EcoRV site.

## EXAMPLE 2

25 The present example demonstrates modulation of apoptosis with apoptosis-specific eIF-5A and DHS.

### *Culturing of COS-7 Cells and Isolation of RNA*

COS-7, an African green monkey kidney fibroblast-like cell line transformed with 30 a mutant of SV40 that codes for wild-type T antigen, was used for all transfection-based experiments. COS-7 cells were cultured in Dulbecco's Modified Eagle's medium (DMEM) with 0.584 grams per liter of L-glutamine, 4.5 g of glucose per liter, and 0.37 %

sodium bicarbonate. The culture media was supplemented with 10 % fetal bovine serum (FBS) and 100 units of penicillin/streptomycin. The cells were grown at 37° C in a humidified environment of 5 % CO<sub>2</sub> and 95 % air. The cells were subcultured every 3 to 4 days by detaching the adherent cells with a solution of 0.25 % trypsin and 1 mM EDTA.

5 The detached cells were dispensed at a split ratio of 1:10 in a new culture dish with fresh media.

COS-7 cells to be used for isolation of RNA were grown in 150-mm tissue culture treated dishes (Corning). The cells were harvested by detaching them with a solution of trypsin-EDTA. The detached cells were collected in a centrifuge tube, and the cells were 10 pelleted by centrifugation at 3000 rpm for 5 minutes. The supernatant was removed, and the cell pellet was flash-frozen in liquid nitrogen. RNA was isolated from the frozen cells using the GenElute Mammalian Total RNA Miniprep kit (Sigma) according to the manufacturer's instructions.

15 *Construction of Recombinant Plasmids and Transfection of COS-7 Cells*

Recombinant plasmids carrying the full-length coding sequence of rat apoptosis eIF-5A in the sense orientation and the 3' untranslated region (UTR) of rat apoptosis eIF-5A in the antisense orientation were constructed using the mammalian epitope tag expression vector, pHM6 (Roche Molecular Biochemicals), which is illustrated in FIG. 21. 20 The vector contains the following: CMV promoter - human cytomegalovirus immediate-early promoter/enhancer; HA - nonapeptide epitope tag from influenza hemagglutinin; BGH pA - Bovine growth hormone polyadenylation signal; f1 ori - f1 origin; SV40 ori - SV40 early promoter and origin; Neomycin - Neomycin resistance (G418) gene; SV40 pA - SV40 polyadenylation signal; Col E1- ColE1 origin; Ampicillin- Ampicillin resistance 25 gene. The full-length coding sequence of rat apoptosis eIF-5A and the 3' UTR of rat apoptosis eIF-5A were amplified by PCR from the original rat eIF-5A RT-PCR fragment in pBluescript (SEQ ID NO:1). To amplify the full-length eIF-5A the primers used were as follows: Forward 5' GCCAAGCTTAATGGCAGATGATT GG 3' (Hind3)(SEQ ID NO:22) and Reverse 5' CTGAATTCCAGT TATTGCGCATGG 3' (EcoR1)(SEQ ID NO:23). To amplify the 3' UTR rat eIF-5A the primers used were as follows: forward 5' 30 AATGAATTCCGCCATGACAGAGGAGGC 3' (EcoR1)(SEQ ID NO:24) and reverse 5'

GCGAAGCTTCCATGGCTCGAGTTTTTTTTTTTTTTTTT 3' (Hind3)(SEQ ID NO:10).

The full-length rat eIF-5A PCR product isolated after agarose gel electrophoresis was 430 bp in length while the 3' UTR rat eIF-5A PCR product was 697 bp in length.

5 Both PCR products were subcloned into the Hind 3 and EcoR1 sites of pHM6 to create pHM6-full-length eIF-5A and pHM6-antisense 3'UTReIF-5A. The full-length rat eIF-5A PCR product was subcloned in frame with the nonapeptide epitope tag from influenza hemagglutinin (HA) present upstream of the multiple cloning site to allow for detection of the recombinant protein using an anti-[HA]-peroxidase antibody. Expression is driven by  
10 the human cytomegalovirus immediate-early promoter/enhancer to ensure high level expression in mammalian cell lines. The plasmid also features a neomycin-resistance (G418) gene, which allows for selection of stable transfecants, and a SV40 early promoter and origin, which allows episomal replication in cells expressing SV40 large T antigen, such as COS-7.

15 COS-7 cells to be used in transfection experiments were cultured in either 24 well cell culture plates (Corning) for cells to be used for protein extraction, or 4 chamber culture slides (Falcon) for cells to be used for staining. The cells were grown in DMEM media supplemented with 10 % FBS, but lacking penicillin/streptomycin, to 50 to 70 % confluence. Transfection medium sufficient for one well of a 24-well plate or culture slide  
20 was prepared by diluting 0.32 µg of plasmid DNA in 42.5 µl of serum-free DMEM and incubating the mixture at room temperature for 15 minutes. 1.6 µl of the transfection reagent, LipofectAMINE (Gibco, BRL), was diluted in 42.5 µl of serum-free DMEM and incubated for 5 minutes at room temperature. After 5 minutes the LipofectAMINE mixture was added to the DNA mixture and incubated together at room temperature for 30  
25 to 60 minutes. The cells to be transfected were washed once with serum-free DMEM before overlaying the transfection medium and the cells were placed back in the growth chamber for 4 hours.

30 After the incubation, 0.17 ml of DMEM + 20 % FBS was added to the cells. The cells were cultured for a further 40 hours before either being induced to undergo apoptosis prior to staining or harvested for Western blot analysis. As a control, mock transfections were also performed in which the plasmid DNA was omitted from the transfection medium.

*Protein Extraction and Western Blotting*

Protein was isolated for Western blotting from transfected cells by washing the cells twice in PBS (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na<sub>2</sub>HPO<sub>4</sub>, and 0.24 g/L KH<sub>2</sub>PO<sub>4</sub>) and then adding 150 µl of hot SDS gel-loading buffer (50 mM Tris-HCl pH 6.8, 100 mM 5 dithiothreitol, 2 % SDS, 0.1 % bromophenol blue, and 10 % glycerol). The cell lysate was collected in a microcentrifuge tube, heated at 95° C for 10 minutes, and then centrifuged at 13,000 x g for 10 minutes. The supernatant was transferred to a fresh microcentrifuge tube and stored at -20° C until ready for use.

For Western blotting, 2.5 or 5 µg of total protein was separated on a 12 % SDS-10 polyacrylamide gel. The separated proteins were transferred to a polyvinylidene difluoride membrane. The membrane was then incubated for one hour in blocking solution (5 % skim milk powder, 0.02 % sodium azide in PBS) and washed three times for 15 minutes in PBS-T (PBS + 0.05 % Tween-20). The membrane was stored overnight in PBS-T at 4 °C. After being warmed to room temperature the next day, the membrane was blocked for 30 15 seconds in 1 µg/ml polyvinyl alcohol. The membrane was rinsed 5 times in deionized water and then blocked for 30 minutes in a solution of 5 % milk in PBS. The primary antibody was preincubated for 30 minutes in a solution of 5 % milk in PBS prior to incubation with the membrane.

Several primary antibodies were used. An anti-[HA]-peroxidase antibody (Roche 20 Molecular Biochemicals) was used at a dilution of 1:5000 to detect expression of the recombinant proteins. Since this antibody is conjugated to peroxidase, no secondary antibody was necessary, and the blot was washed and developed by chemiluminescence. The other primary antibodies that were used are monoclonal antibodies from Oncogene 25 that recognize p53 (Ab-6), Bcl-2 (Ab-1), and c-Myc (Ab-2). The monoclonal antibody to p53 was used at a dilution of 0.1 µg/ml, and the monoclonal antibodies to Bcl-2 and c-Myc were both used at a dilution of 0.83 µg/ml. After incubation with primary antibody for 60 to 90 minutes, the membrane was washed 3 times for 15 minutes in PBS-T. Secondary antibody was then diluted in 1 % milk in PBS and incubated with the membrane for 60 to 90 minutes. When p53 (Ab-6) was used as the primary antibody, the secondary antibody 30 used was a goat anti-mouse IgG conjugated to alkaline phosphatase (Rockland) at a dilution of 1:1000. When Bcl-2 (Ab-1) and c-Myc (Ab-2) were used as the primary antibody, a rabbit anti-mouse IgG conjugated to peroxidase (Sigma) was used at a dilution

of 1:5000. After incubation with the secondary antibody, the membrane was washed 3 times in PBS-T.

Two detection methods were used to develop the blots, a colorimetric method and a chemiluminescent method. The colorimetric method was used only when p53 (Ab-6) 5 was used as the primary antibody in conjunction with the alkaline phosphatase-conjugated secondary antibody. Bound antibody was visualized by incubating the blot in the dark in a solution of 0.33 mg/mL nitro blue tetrazolium, 0.165 mg/mL 5-bromo-4-chloro-3-indolyl phosphate, 100 mM NaCl, 5 mM MgCl<sub>2</sub>, and 100 mM Tris-HCl (pH 9.5). The color reaction was stopped by incubating the blot in 2 mM EDTA in PBS. A chemiluminescent 10 detection method was used for all other primary antibodies, including anti-[HA]-peroxidase, Bcl-2 (Ab-1), and c-Myc (Ab-2). The ECL Plus Western blotting detection kit (Amersham Pharmacia Biotech) was used to detect peroxidase-conjugated bound 15 antibodies. In brief, the membrane was lightly blotted dry and then incubated in the dark with a 40:1 mix of reagent A and reagent B for 5 minutes. The membrane was blotted dry, placed between sheets of acetate, and exposed to X-ray film for time periods varying from 10 seconds to 10 minutes.

#### *Induction of Apoptosis in COS 7 Cells*

Two methods were used to induce apoptosis in transfected COS-7 cells, serum 20 deprivation and treatment with Actinomycin D, *streptomyces* sp (Calbiochem). For both treatments, the medium was removed 40 hours post-transfection. For serum starvation experiments, the media was replaced with serum- and antibiotic-free DMEM. Cells grown in antibiotic-free DMEM supplemented with 10 % FBS were used as a control. For Actinomycin D induction of apoptosis, the media was replaced with antibiotic-free DMEM 25 supplemented with 10 % FBS and 1 µg/ml Actinomycin D dissolved in methanol. Control cells were grown in antibiotic-free DMEM supplemented with 10 % FBS and an equivalent volume of methanol. For both methods, the percentage of apoptotic cells was determined 48 hours later by staining with either Hoescht or Annexin V-Cy3. Induction of apoptosis was also confirmed by Northern blot analyses, as shown in FIG. 22.

*Hoescht Staining*

The nuclear stain, Hoescht, was used to label the nuclei of transfected COS-7 cells in order to identify apoptotic cells based on morphological features such as nuclear fragmentation and condensation. A fixative, consisting of a 3:1 mixture of absolute 5 methanol and glacial acetic acid, was prepared immediately before use. An equal volume of fixative was added to the media of COS-7 cells growing on a culture slide and incubated for 2 minutes. The media/fixative mixture was removed from the cells and discarded, and 1 ml of fixative was added to the cells. After 5 minutes the fixative was discarded, and 1 ml of fresh fixative was added to the cells and incubated for 5 minutes. 10 The fixative was discarded, and the cells were air-dried for 4 minutes before adding 1 ml of Hoescht stain (0.5 µg/ml Hoescht 33258 in PBS). After a 10-minute incubation in the dark, the staining solution was discarded and the slide was washed 3 times for 1 minute with deionized water. After washing, 1 ml of McIlvaine's buffer (0.021 M citric acid, 0.058 M Na<sub>2</sub>HPO<sub>4</sub>.7H<sub>2</sub>O; pH 5.6) was added to the cells, and they were incubated in the 15 dark for 20 minutes. The buffer was discarded, the cells were air-dried for 5 minutes in the dark and the chambers separating the wells of the culture slide were removed. A few drops of Vectashield mounting media for fluorescence (Vector Laboratories) was added to the slide and overlaid with a coverslip. The stained cells were viewed under a fluorescence microscope using a UV filter. Cells with brightly stained or fragmented 20 nuclei were scored as apoptotic.

*Annexin V-Cy3 Staining*

An Annexin V-Cy3 apoptosis detection kit (Sigma) was used to fluorescently label externalized phosphatidylserine on apoptotic cells. The kit was used according to the 25 manufacturer's protocol with the following modifications. In brief, transfected COS-7 cells growing on four chamber culture slides were washed twice with PBS and three times with 1 X Binding Buffer. 150 µl of staining solution (1 µg/ml AnnCy3 in 1 X Binding Buffer) was added, and the cells were incubated in the dark for 10 minutes. The staining solution was then removed, and the cells were washed 5 times with 1 X Binding Buffer. 30 The chamber walls were removed from the culture slide, and several drops of 1 X Binding Buffer were placed on the cells and overlaid with a coverslip. The stained cells were analyzed by fluorescence microscopy using a green filter to visualize the red fluorescence

of positively stained (apoptotic) cells. The total cell population was determined by counting the cell number under visible light.

### EXAMPLE 3

5 The present example demonstrates modulation of apoptosis with apoptosis-specific eIF-5A and DHS.

Using the general procedures and methods described in the previous examples, FIG. 23 is a flow chart illustrating the procedure for transient transfection of COS-7 cells, in which cells in serum-free medium were incubated in plasmid DNA in lipofectAMINE 10 for 4 hours, serum was added, and the cells were incubated for a further 40 hours. The cells were then either incubated in regular medium containing serum for a further 48 hours before analysis (i.e. no further treatment), deprived of serum for 48 hours to induce apoptosis before analysis, or treated with actinomycin D for 48 hours to induce apoptosis before analysis.

15 FIG. 22 is a Western blot illustrating transient expression of foreign proteins in COS-7 cells following transfection with pHM6. Protein was isolated from COS-7 cells 48 hours after either mock transfection, or transfection with pHM6-LacZ, pHM6-Antisense 3' rF5A (pHM6-Antisense 3' UTR rat apoptosis eIF-5A), or pHM6-Sense rF5A (pHM6-Full length rat apoptosis eIF-5A). Five µg of protein from each sample was fractionated by 20 SDS-PAGE, transferred to a PVDF membrane, and Western blotted with anti-[HA]-peroxidase. The bound antibody was detected by chemiluminescence and exposed to x-ray film for 30 seconds. Expression of LacZ (lane 2) and of sense rat apoptosis eIF-5A (lane 4) is clearly visible.

As described above, COS-7 cells were either mock transfected or transfected with 25 pHM6-Sense rF5A (pHM6-Full length rat eIF-5A). Forty hours after transfection, the cells were induced to undergo apoptosis by withdrawal of serum for 48 hours. The caspase proteolytic activity in the transfected cell extract was measured using a fluorometric 30 homogenous caspase assay kit (Roche Diagnostics). DNA fragmentation was also measured using the FragEL DNA Fragmentation Apoptosis Detection kit (Oncogene) which labels the exposed 3'-OH ends of DNA fragments with fluorescein-labeled deoxynucleotides.

Additional COS-7 cells were either mock transfected or transfected with pHM6-Sense rF5A (pHM6-Full length rat eIF-5A). Forty hours after transfection, the cells were either grown for an additional 48 hours in regular medium containing serum (no further treatment), induced to undergo apoptosis by withdrawal of serum for 48 hours or induced 5 to undergo apoptosis by treatment with 0.5 µg/ml of Actinomycin D for 48 hours. The cells were either stained with Hoescht 33258, which depicts nuclear fragmentation accompanying apoptosis, or stained with Annexin V-Cy3, which depicts phosphatidylserine exposure accompanying apoptosis. Stained cells were also viewed by fluorescence microscopy using a green filter and counted to determine the percentage of 10 cells undergoing apoptosis. The total cell population was counted under visible light.

FIG. 25 illustrates enhanced apoptosis as reflected by increased caspase activity when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in the sense orientation. Expression of rat apoptosis-induced eIF-5A resulted in a 60% increase in caspase activity.

15 FIG. 26 illustrates enhanced apoptosis as reflected by increased DNA fragmentation when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in the sense orientation. Expression of rat apoptosis-induced eIF-5A resulted in a 273% increase in DNA fragmentation. FIG. 27 illustrates detection of apoptosis as reflected by increased nuclear fragmentation when COS-7 cells 20 were transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in the sense orientation. There is a greater incidence of fragmented nuclei in cells expressing rat apoptosis-induced eIF-5A. FIG. 28 illustrates enhanced apoptosis as reflected by increased nuclear fragmentation when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in the sense 25 orientation. Expression of rat apoptosis-induced eIF-5A resulted in a 27 % and 63 % increase in nuclear fragmentation over control in non-serum starved and serum starved samples, respectively.

FIG. 29 illustrates detection of apoptosis as reflected by phosphatidylserine exposure when COS-7 cells were transiently transfected with pHM6 containing full-length 30 rat apoptosis-induced eIF-5A in the sense orientation. FIG. 30 illustrates enhanced apoptosis as reflected by increased phosphatidylserine exposure when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in

the sense orientation. Expression of rat apoptosis-induced eIF-5A resulted in a 140 % and 198 % increase in phosphatidylserine exposure over control, in non-serum starved and serum starved samples, respectively.

FIG. 31 illustrates enhanced apoptosis as reflected by increased nuclear fragmentation when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in the sense orientation. Expression of rat apoptosis-induced eIF-5A resulted in a 115 % and 62 % increase in nuclear fragmentation over control in untreated and treated samples, respectively. FIG. 32 illustrates a comparison of enhanced apoptosis under conditions in which COS-7 cells transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in the sense orientation were either given no further treatment or treatment to induce apoptosis.

#### EXAMPLE 4

The present example demonstrates modulation of apoptotic activity following administration of apoptosis-specific eIF-5A and DHS.

Moreover, COS-7 cells were either mock transfected, transfected with pHM6-LacZ or transfected with pHM6-Sense rF5A (pHM6-Full length rat eIF-5A) and incubated for 40 hours. Five  $\mu$ g samples of protein extract from each sample were fractionated by SDS-PAGE, transferred to a PVDF membrane, and Western blotted with a monoclonal antibody that recognizes Bcl-2. Rabbit anti-mouse IgG conjugated to peroxidase was used as a secondary antibody, and bound antibody was detected by chemiluminescence and exposure to x-ray film. Results are shown in FIG. 32. Less Bcl-2 is detectable in cells transfected with pHM6-Sense rF5A than in those transfected with pHM6-LacZ; therefore, Bcl-2 is down-regulated.

Additional COS-7 cells were either mock transfected, transfected with pHM6-antisense 3' rF5A (pHM6-antisense 3' UTR of rat apoptosis-specific eIF-5A) or transfected with pHM6-Sense rF5A (pHM6-Full length rat apoptosis-specific eIF-5A). Forty hours after transfection, the cells were induced to undergo apoptosis by withdrawal of serum for 48 hours. Five  $\mu$ g samples of protein extract from each sample were fractionated by SDS-PAGE, transferred to a PVDF membrane, and Western blotted with a monoclonal antibody that recognizes Bcl-2. Rabbit anti-mouse IgG conjugated to peroxidase was used as a

secondary antibody, and bound antibody was detected by chemiluminescence and exposure to x-ray film.

Also additionally, COS-7 cells were either mock transfected, transfected with pHM6-LacZ or transfected with pHM6-Sense rF5A (pHM6-Full length rat eIF-5A) and 5 incubated for 40 hours. Five µg samples of protein extract from each sample were fractionated by SDS-PAGE, transferred to a PVDF membrane, and Western blotted with a monoclonal antibody that recognizes p53. Goat anti-mouse IgG conjugated to alkaline phosphatase was used as a secondary antibody, and bound antibody was detected a colorimetrically.

10 Finally, COS-7 cells were either mock transfected, transfected with pHM6-LacZ or transfected with pHM6-Sense rF5A (pHM6-Full length rat eIF-5A) and incubated for 40 hours. Five µg samples of protein extract from each sample were fractionated by SDS-PAGE, transferred to a PVDF membrane, and probed with a monoclonal antibody that recognizes p53. Corresponding protein blots were probed with anti-[HA]-peroxidase to 15 determine the level of rat apoptosis-specific eIF-5A expression. Goat anti-mouse IgG conjugated to alkaline phosphatase was used as a secondary antibody, and bound antibody was detected by chemiluminescence.

20 FIG. 33 illustrates downregulation of Bcl-2 when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in the sense orientation. The upper panel illustrates the Coomassie-blue-stained protein blot; the lower panel illustrates the corresponding Western blot. Less Bcl-2 is detectable in cells transfected with pHM6-Sense rF5A than in those transfected with pHM6-LacZ.

25 FIG. 34 illustrates upregulation of Bcl-2 when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in the antisense orientation. The upper panel illustrates the Coomassie-blue-stained protein blot; the lower panel illustrates the corresponding Western blot. More Bcl-2 is detectable in cells transfected with pHM6-antisense 3' rF5A than in those mock transfected or transfected with pHM6-Sense rF5A.

30 FIG. 35 illustrates upregulation of c-Myc when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in the sense orientation. The upper panel illustrates the Coomassie-blue-stained protein blot; the lower panel illustrates the corresponding Western blot. More c-Myc is detectable in cells

transfected with pHM6-Sense rF5A than in those transfected with pHM6-LacZ or the mock control.

FIG. 36 illustrates upregulation of p53 when COS-7 cells were transiently transfected with pHM6 containing full-length rat apoptosis-induced eIF-5A in the sense orientation. The upper panel illustrates the Coomassie-blue-stained protein blot; the lower panel illustrates the corresponding Western blot. More p53 is detectable in cells transfected with pHM6-Sense rF5A than in those transfected with pHM6-LacZ or the mock control.

FIG. 37 illustrates the dependence of p53 upregulation upon the expression of pHM6-full length rat apoptosis-induced eIF-5A in COS-7 cells. In the Western blot probed with anti-[HA]-peroxidase, the upper panel illustrates the Coomassie-blue-stained protein blot and the lower panel illustrates the corresponding Western blot. More rat apoptosis-induced eIF-5A is detectable in the first transfection than in the second transfection. In the Western blot probed with anti-p53, the upper panel in A illustrates a corresponding Coomassie-blue-stained protein blot and the lower panel illustrates the Western blot with p53. For the first transfection, more p53 is detectable in cells transfected with pHM6-Sense rF5A than in those transfected with pHM6-LacZ or the mock control. For the second transfection in which there was less expression of rat apoptosis-induced eIF-5A, there was no detectable difference in levels of p53 between cells transfected with pHM6-Sense rF5A, pHM6-LacZ or the mock control.

#### EXAMPLE 5

The present example demonstrates that apoptosis-specific eIF-5A can induce apoptosis in cells with active p53 (RKO cells) and in cells without active p53 (RKO-E6 cells), indicating that apoptosis-specific eIF-5A can initiate apoptosis through pathway(s) other than the p53 pathway. This also supports our contention that it is acting upstream and likely able to kill a wide range of different types of cancers.

The present example also indicates that the active site of eIF-5A1 is the carboxy terminus of the protein ( i.e. see experiments with truncated eIF-5A1), which most likely contains the RNA binding domain.

Further, the present example also demonstrates that human eIF-5A2 is most likely a proliferating eIF-5A as it is unable to induce apoptosis. Thus, it is believed that of the

two eIF-5A genes in the human data bank, apoptosis-specific eIf-5A1 is the apoptosis gene, and eIF-5A2 is the proliferation gene.

*Culture of RKO and RKO-E6 Cells*

5 RKO (American Type Culture Collection CRL-2577), a human colon carcinoma cell line expressing wild-type p53, and RKO-E6 (American Type Culture Collection CRL-2578), a cell line derived from RKO that contains a stably integrated human papilloma virus E6 oncogene that causes a decrease in normal p53 level and function, were used for transfection-based experiments. RKO and RKO-E6 cells were cultured in Minimum  
10 Essential Medium Eagle (MEM) with non-essential amino acids, Earle's salts, and L-glutamine. The culture media was supplemented with 10 % fetal bovine serum (FBS) and 100 units of penicillin/streptomycin. The cells were grown at 37°C in a humidified environment of 5 % CO<sub>2</sub> and 95 % air. The cells were subcultured every 3 to 4 days by detaching the adherent cells with a solution of 0.25 % trypsin and 1 mM EDTA. The  
15 detached cells were dispensed at a split ratio of 1:10 to 1:12 into a new culture dish with fresh media.

*Cloning of human eIF5A2*

Human eIF5A2 was isolated by RT-PCR from RNA isolated from RKO cells using  
20 primers designed against the sequence of human eIF5A2 available from GenBank (ACCESSION XM\_113401). Figure 38 provides an alignment of human eIF-5A isolated from RKO cells with the sequence of human eIF-5A2. RNA was isolated from RKO cells using the GenElute Mammalian Total RNA Miniprep Kit (Sigma). The forward primer used to amplify eIF5A2 had the sequence 5' AAACTACCATCTCCCCTGCC 3' (SEQ ID NO:25) and the reverse primer had the sequence 5' TGCCCTACACAGGGCTGAAAG 3' (SEQ ID NO:26). The resulting 936 bp PCR product was subcloned into the pGEM-T  
25 Easy Vector (Promega) and sequenced.

The pGEM-T Easy-eIF5A2 construct was then used as template to generate a eIF5A2 PCR fragment to be subcloned in frame into the mammalian expression vector  
30 pHM6 (Roche). The forward primer used to amplify human eIF5A2 was 5' ATCAAGCTTGCACCATGGCAGACG 3' (SEQ ID NO:27) and the reverse primer was 5' AACGAATTCCATGCCTGATGTTCCG 3' (SEQ ID NO:28). The resulting 505

bp PCR product was digested with Hind 3 and EcoR 1 and subcloned into the Hind 3 and EcoR1 sites of pHM6.

*Construction of pHM6-truncated eIF5A1*

5 In order to determine if the carboxy-terminal region of eIF5A1 is important for its apoptosis-inducing activity, a carboxy-terminal deleted eIF5A1 was constructed. The truncated eIF5A1, coding for amino acids 1 to 127, was generated by PCR using pBS-rat eIF5A1 as template. The forward PCR primer was 5'  
GCCAAGCTTAATGGCAGATGATTGG 3' (SEQ ID NO:22) and the reverse primer  
10 was 5' TCCGAATTCGTACTTCTGCTCAATC 3' (SEQ ID NO:29). The resulting 390 bp PCR product was digested with EcoR 1 and Hind 3 and subcloned into the EcoR 1 and Hind 3 sites of pHM6.

*Transfection*

15 RKO or RKO-E6 cells to be used in transfection experiments were cultured in 8 well chamber culture slides (Falcon) for cells to be used for Hoescht staining or 6 well plates for cells to be analyzed by flow cytometry. The cells were grown in MEM media supplemented with 10 % FBS but lacking penicillin/streptomycin to 70 to 80 % confluence. Transfection medium sufficient for one well of an 8 well culture slide was  
20 prepared by diluting 0.425 µg of plasmid DNA in 22 µl of serum-free MEM and incubating the mixture at room temperature for 15 minutes. 0.85 µl of the transfection reagent, LipofectAMINE (Gibco, BRL), was diluted in 22 µl of serum-free MEM and incubated for 5 minutes at room temperature. After 5 minutes the LipofectAMINE mixture was added to the DNA mixture and incubated at room temperature for 30 to 60  
25 minutes. The cells to be transfected were washed once with serum-free MEM before adding 44 µl of MEM to the transfection medium and overlaying it over the cells. The cells were placed back in the growth chamber for 4 hours. After the incubation, 88 µl of MEM + 20 % FBS was added to the cells. The cells were then cultured for a further 44 hours and then stained with Hoescht 33258 as previously described. In another set of  
30 experiments, RKO or RKO-E6 cells in 8-well culture slides were treated with 0.25 µg/ml Actinomycin D 24 hours after transfection and stained with Hoescht 20 hours later. Transfections carried out in 6-well plates were performed in the same manner except that

all the reagents were increased by 4.81 times. RKO cells transfected in 6 well plates were harvested 48 hours after transfection and fixed for analysis by flow cytometry as described below.

5 *Determination of Transfection Efficiency*

The efficiency of transfection was determined by staining pHM6-LacZ-transfected cells with 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-GAL). Blue-stained cells are LacZ-expressing transfected cells, and transfection efficiency was calculated as the number of blue stained cells divided by the total number of cells. Transfected cells 10 were stained 48 hours following transfection. The cells were washed twice with PBS and then fixed for 10 minutes at room temperature in 0.5 % gluteraldehyde/PBS. The cells were washed three times with 1 mM MgCl<sub>2</sub>/PBS and then incubated with staining solution [5 mM K<sub>4</sub>Fe(CN)<sub>6</sub>.3H<sub>2</sub>O, 5 mM K<sub>3</sub>Fe(CN)<sub>6</sub>, 1 mM MgCl<sub>2</sub>, 0.1 % X-GAL in PBS] until blue-stained cells appeared.

15

*Hoescht Staining*

The nuclear stain, Hoescht, was used to label the nuclei of transfected RKO and RKO-E6 cells in order to identify apoptotic cells based on nuclear fragmentation and condensation. A fixative, consisting of a 3:1 mixture of absolute methanol and glacial 20 acetic acid, was prepared immediately before use. An equal volume of fixative was added to the media of cells growing on a culture slide and incubated for 2 minutes. The media/fixative mixture was removed from the cells and discarded, and 1 ml of fixative was added to the cells. After 5 minutes the fixative was discarded and 1 ml of fresh fixative was added to the cells and incubated for 5 minutes. The fixative was discarded and the 25 cells were air-dried for 4 minutes before adding 1 ml of Hoescht stain (0.5 µg/ml Hoescht 33258 in PBS). After a 10 minute incubation in the dark, the staining solution was discarded and the slide was washed 3 times for 1 minute with deionized water. After washing, 1 ml of McIlvaine's buffer (0.021 M citric acid, 0.058 M Na<sub>2</sub>HPO<sub>4</sub>.7H<sub>2</sub>O; pH 5.6) was added to the cells and incubated in the dark for 20 minutes. The buffer was 30 discarded and the cells were air-dried for 5 minutes in the dark and the chambers separating the wells of the culture slide were removed. A few drops of Vectashield mounting media for fluorescence (Vector Laboratories) was added to the slide and

overlayed with a coverslip. The stained cells were viewed under a fluorescent microscope using a UV filter. Cells with brightly stained or fragmented nuclei were scored as apoptotic.

5 *DNA Fragmentation Detection by Flow Cytometry*

DNA fragments generated during apoptosis were labeled with fluorescein-labeled deoxynucleotides using the Fluorescein-FragELTM DNA Fragmentation Detection Kit (Oncogene Research Products). Cells transfected with various constructs in 6 well culture plates were harvested by trypsinization 48 hours after transfection and fixed and labeled 10 according to the manufacturer's instructions. Briefly, the cells were pelleted at 1000 x g for 5 minutes at 4°C and washed once in PBS (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na<sub>2</sub>HPO<sub>4</sub>, and 0.24 g/L KH<sub>2</sub>PO<sub>4</sub>). The cells were resuspended in 4% formaldehyde/PBS and incubated at room temperature for 10 minutes. The cells were pelleted again, 15 resuspended in 1 ml of 80 % ethanol, and stored at 4°C. On the day of analysis, 1 ml of fixed cells (at 1 X 10<sup>6</sup> cells/ml) was transferred to a microfuge tube and the cells pelleted by centrifugation at 1000 x g for 5 minutes. The pelleted cells were resuspended in 200 µl of 1 X TBS (20 mM Tris pH 7.6, 140 mM NaCl) and incubated 10 to 15 minutes at room temperature. The cells were then pelleted again and resuspended in 100 µl of 20 µg/ml proteinase K and incubated for 5 minutes at room temperature. The cells were pelleted 20 and resuspended in 100 µl of 1 X TdT Equilibration buffer and incubated at room temperature for 10 to 30 minutes. The cells were then pelleted by centrifugation and resuspended in 60 µl of TdT Labeling Reaction Mixture and incubated for 1 to 1.5 hours in the dark. After the incubation, the cells were pelleted by centrifugation and washed twice in 200 µl of 1 X TBS. The cells were resuspended in a final volume of 0.5 ml 1 X TBS 25 and analyzed on a flow cytometer equipped with a 488 nm argon ion laser source.

*Protein Extraction and Western Blotting*

Protein was isolated for Western blotting from transfected cells by washing the cells twice in PBS and then adding 150 µl of hot SDS gel-loading buffer (50 mM Tris-HCl 30 pH 6.8, 100 mM dithiothreitol, 2 % SDS, 0.1 % bromophenol blue, and 10 % glycerol). The cell lysate was collected in a microcentrifuge tube, heated at 95 °C for 10 minutes, and

then centrifuged at 13,000 X g for 10 minutes. The supernatant was transferred to a fresh microcentrifuge tube and stored at -20 °C until ready for use.

For Western blotting, 5 µg or 10 µg of total protein was separated on a 12 % SDS-polyacrylamide gel. The separated proteins were transferred to a polyvinylidene difluoride membrane. The membrane was then incubated for one hour in blocking solution (5 %

5

skim milk powder, 0.02 % sodium azide in PBS) and washed three times for 15 minutes in PBS-T (PBS + 0.05 % Tween-20). The membrane was stored overnight in PBS-T at 4 °C.

After being warmed to room temperature the next day, the membrane was blocked for 30 seconds in 1 µg/ml polyvinyl alcohol. The membrane was rinsed 5 times in deionized 10 water and then blocked for 30 minutes in a solution of 5 % milk in PBS. The primary antibody was preincubated for 30 minutes in a solution of 5 % milk in PBS/0.025% Tween-20 prior to incubation with the membrane.

The membranes were blotted with either a monoclonal antibody from Oncogene which recognizes p53 (Ab-6), or a polyclonal antibody directed against a synthetic peptide

15

(amino-CRLPEGDLGKEIEQKYD-carboxy) (SEQ ID NO:30) homologous to the C-terminal end of human eIF5A1 that was raised in chickens. The monoclonal antibody to

p53 was used at a dilution of 0.1 µg/ml and the antibody against eIF5A1 was used at a dilution of 1:1000. After incubation with primary antibody for 60 to 90 minutes, the membrane was washed 3 times for 15 minutes in PBS-T. Secondary antibody was then

20

diluted in 1 % milk in PBS/0.025 % Tween-20 and incubated with the membrane for 60 to 90 minutes. When p53 (Ab-6) was used as the primary antibody, the secondary antibody

used was a goat anti-mouse IgG conjugated to alkaline phosphatase (Rockland) at a dilution of 1:1000. When anti-eIF5A1 was used as the primary antibody, a rabbit anti-chicken IgY conjugated to peroxidase (Gallus Immunotech) was used at a dilution of

25

1:10000. After incubation with the secondary antibody, the membrane was washed 3 times in PBS-T.

Two detection methods were used to develop the blots, a colourimetric method and a chemiluminescent method. The colourimetric method was used only when p53 (Ab-6) was used as the primary antibody in conjunction with the alkaline phosphatase-conjugated 30 secondary antibody. Bound antibody was visualized by incubating the blot in the dark in a solution of 0.33 mg/mL nitro blue tetrazolium, 0.165 mg/mL 5-bromo-4-chloro-3-indolyl phosphate, 100 mM NaCl, 5 mM MgCl<sub>2</sub>, and 100 mM Tris-HCl (pH 9.5). The color

reaction was stopped by incubating the blot in 2 mM EDTA in PBS. A chemiluminescent detection method was used for all other primary antibodies, including anti-[HA]-peroxidase and anti-eIF5A1. The ECL Plus Western blotting detection kit (Amersham Pharmacia Biotech) was used to detect peroxidase-conjugated bound antibodies. In brief, 5 the membrane was lightly blotted dry and then incubated in the dark with a 40:1 mix of reagent A and reagent B for 5 minutes. The membrane was blotted dry, placed between sheets of acetate, and exposed to X-ray film for time periods varying from 10 seconds to 30 minutes.

Figure 39 shows a graph depicting the percentage of apoptosis occurring in RKO 10 and RKO-E6 cells following transient transfection. RKO and RKO-E6 cells were transiently transfected with pHM6-LacZ or pHM6-eIF5A1. 24 hours later, the cells were treated either with 0.25 µg/ml Actinomycin D or an equivalent volume of methanol (control). The cells were stained with Hoescht 20 hours later and were viewed under a fluorescent microscope using a UV filter. Cells that stained brightly due to condensed 15 chromatin were scored as apoptotic. The experiments above reveal that RKO cells treated with Actinomycin D and transfected with pHM6-eIF5A1 showed a 240% increase in apoptosis relative to cells transfected with pHM6-LacZ that were not treated with Actinomycin D. RKO-E6 cells treated with Actinomycin D and transfected with pHM6-eIF5A1 showed a 105% increase in apoptosis relative to cells transfected with pHM6-LacZ 20 that were not treated with Actinomycin D.

Figure 40 provides a graph depicting the percentage of apoptosis occurring in RKO cells following transient transfection. RKO cells were transiently transfected with pHM6-LacZ, pHM6-eIF5A1, pHM6-eIF5A2, or pHM6-truncated eIF5A1. The cells were stained with Hoescht 44 hours later and were viewed under a fluorescent microscope using a UV filter. Cells that stained brightly due to condensed chromatin were scored as apoptotic. 25 Cells transfected with pHM6-eIF5A1 showed a 25% increase in apoptosis relative to control cells transfected with pHM6-LacZ. This increase was not apparent for cells transfected with pHM6-eIF5A2 or pHM6-truncated eIF5A1.

Figure 41 provides a graph depicting the percentage of apoptosis occurring in RKO 30 cells following transient transfection. RKO cells were either left untransfected or were transiently transfected with pHM6-LacZ or pHM6-eIF5A1. The cells were stained with Hoescht 44 hours later and were viewed under a fluorescent microscope using a UV filter.

Cells that stained brightly due to condensed chromatin were scored as apoptotic. After correction for transfection efficiency, 60 % of the cells transfected with pHM6-eIF5A1 were apoptotic.

Figure 42 provides flow cytometry analysis of RKO cell apoptosis following 5 transient transfection. RKO cells were either left untransfected or were transiently transfected with pHM6-LacZ, pHM6-eIF5A1, pHM6-eIF5A2, or pHM6-truncated eIF5A1. 48 hours later the cells were harvested and fixed. Fragmented DNA reflecting apoptosis was labeled with fluorescein-conjugated deoxynucleotides and analyzed on a flow 10 cytometer equipped with a 488 nm argon ion laser source. Fluorescence occurring under gate E is from non-apoptotic cells, and fluorescence occurring under gate F is from cells undergoing apoptosis. The table depicts the percentage of cells undergoing apoptosis 15 calculated based on the area under the peak of each gate. After correction for background apoptosis in untransfected cells and for transfection efficiency, 80% of cells transfected with pHM6-eIF5A1 exhibited apoptosis. Cells transfected with pHM6-LacZ, pHM6- eIF5A2 or pHM6-truncated eIF5A1 exhibited only background levels of apoptosis.

Figure 43 provides Western blots of protein extracted from RKO cells treated with 0.25  $\mu$ g/ml Actinomycin D for 0, 3, 7, 24, and 48 hours. 5  $\mu$ g (for anti-eIF5A1) or 10  $\mu$ g (for anti-p53) of total protein was separated on a 12 % SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. The top panel depicts a Western blot 20 using anti-p53 as the primary antibody. The middle panel depicts a Western blot using anti-eIF5A1 as the primary antibody. The bottom panel depicts the membrane used for the anti-eIF5A1 blot stained with Coomassie blue following chemiluminescent detection to demonstrate equal loading. p53 and eIF5A1 are both upregulated by treatment with Actinomycin D.

25

#### EXAMPLE 6

Figure 47 depicts an experiment run on heart tissue to mimic the beating of a 30 human heart and the subsequent induced heart attack. Figure 49 shows the laboratory bench set up. A slice of human heart tissue removed during valve replacement surgery was hooked up to electrodes. A small weight was attached to the heart tissue to ease in measuring the strength of the heart beats. The electrodes provided an electrical stimulus to get the tissue to start beating. The levels of gene expression for both apoptosis-specific

5 eIF-5A (eIF-5a) and proliferating eIF-5A (eIF5b) were measured in the heart tissue before ischemia was induced. See Figure 46. In the pre-ischemic heart tissue low levels of both eIF-5a and 5eIFb were produced and their levels were in relative balance. During this time, oxygen and carbon dioxide were delivered in a buffer to the heart at 92.5% and 7.5  
10 %, respectively. Later, the oxygen levels was reduced and the nitrogen levels was increased, to induce ischemia and finally a "heart attack." The heart tissue stopped beating. The oxygen levels were then returned to normal, the heart tissue was pulsed again with an electrical stimulus to start the heart beating again. After the "heart attack" the expression levels of apoptosis-specific eIF-5a and proliferating eIF-5A (eIF5b) were again measured. This time, there was a significant increase in the level of expression of the apoptosis-specific eIF-5A levels, whereas the increase in the level of expression of proliferating eIF-5A (eIF5b) was noticeably less. See Figure 46.

15 After the "heart attack" the heart did not beat as strong, as indicated by less compression/movement of the attached weight, thus indicating that the heart tissue cells were being killed rapidly due to the presence of apoptosis-specific eIF-5A.

The EKG results are depicted in Figure 48. On the left side of the panels a normal heart beat is shown (the pre-ischemic heart tissue). After the "heart attack" (straight line), and the re-initiation of the heart beat, the EKG shows decreased activity due to muscle cell death. The EKG shows relative loss in strength of heart beat.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A method of identifying an incidence of ischemia in a mammalian tissue, the method comprising
  - 5 a. measuring gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A in the tissue
  - b. comparing the expression level of apoptosis-specific eIF5a with the expression levels of proliferating eIF-5A in the tissue
  - c. correlating an incidence of ischemia in the tissue when the expression level 10 of apoptosis-specific eIF5a is higher than the expression level of proliferating eIF-5A.
2. The method of claim 1 wherein the tissue is heart tissue.
3. A method of reducing apoptosis in mammalian tissue, the method comprising
  - 15 a. measuring gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A in mammalian tissue
  - b. comparing the levels of expression of apoptosis-specific eIF-5A with the expression levels of proliferating eIF-5A in the mammalian tissue
  - c. correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5A is higher than the expression level of proliferating eIF-5A
  - 20 d. providing to the heart tissue of a mammal an agent that inhibits expression of apoptosis-specific eIF-5A.
4. The method of claim 3 wherein the mammalian tissue is heart tissue.
5. The method of claim 4 wherein the agent is an antisense oligonucleotide comprising an oligonucleotide complementary to a nucleotide sequence encoding an 25 apoptosis-specific eIF-5A.
6. The method of claim 5 wherein the nucleotide sequence encoding an apoptosis-specific eIF-5A is selected from the group consisting of SEQ ID NO: 3 or 4.
7. A method according to any one of claims 1 to 6, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the 30 accompanying examples.

TCGAAGACCGGTAAGCACGGCCATGCCAAGGTCCATCTGGTGGTATTGATATTTTACTGGGAAGAAATAT  
S K T G K H G H A K V H L V G I D I F T G K K Y  
GAAGATATCTGCCCGTCGACTCATAACATGGATGTCCCCAACATCAAAGGAATGATTCCAGCTGATTGGC  
E D I C P S T H N M D V P N I K R N D F Q L I G  
ATCCAGGATGGGTACCTATCCCTGCTCCAGGACAGTGGGGAGGTACGAGAGGACCTCGTCTGCCTGAGGG  
I Q D G Y L S L L Q D S G E V R E D L R L P E G  
GACCTTGGCAAGGAGATTGAGCAGAAGTATGACTGTGGAGAAGAGATCCTGATCACAGTGCTGTCCGCCATG  
D L G K E I E Q K Y D C G E E I L I T V L S A M  
ACAGAGGAGGCAGCTGGTCAATCAAGGCCATGGCAAAATAACTGGCTTCCAGGGTGGCGGTGGCAGCA  
T E E A A V A I K A M A K  
GTGATCCATGAGCCTACAGAGGCCCTCCCCCAGCTCTGGCTGGCCCTTGGCTGGACTCCATCCAATTAA  
TTTGACGTTTATTTGGTTTCTCACCCCTCAAACGTGCGGGAGACCCCTGCCCTCACCTAGCTCCCT  
TGGCCAGGCATGAGGGAGCCATGGCCTTGGTGAAGCTACCTGCCTCTCGCAGCCCTGATGGGGAAA  
GGGAGTGGTACTGCCTGTGGTTAGGTTCCCTCTCCCTTTCTTTCAATTCAATTGGAATCAGAAAG  
CTGTGGATTCTGGCAAATGGCTTGTGTCCTTATCCCACTCAAACCCATCTGGTCCCTGTTCTCCATAGT  
CCTTCACCCCCAAGCACCCTGACAGACTGGGGACCAGCCCCCTCCCTGCCTGTCCTCTCCAAACCC  
TCTATAGGGGTGACAAGAAGAGGAGGGGGAGGGGACACGATCCCTCAGGCATCTGGGAAGGCCTTGC  
CCCCATGGGCTTACCCCTTCTGTGGGCTTCTCCCTGACACATTGTTAAAATCAAACCTGAATAAAC  
TACAAGTTTAATATGAAAAA  
(972 NT, 109 aa)

**FIG.1**

CAGGTCTAGAGTTGGAATCGAAGCCTCTTAAATGGCAGATGATTGGACTTCGAGACAGGAGATGCAGGGG  
M A D D L D F E T G D A G  
CCTCAGCCACCTTCCCAATGCAGTGCTCAGCATTACGTAAGAATGGTTTGCTCAAGGGCCGGCCAT  
A S A T F P M Q C S A L R K N G F V V L K G R P  
GTAAGATCGTCGAGATGTCTACTTCAAGACTGGCAAGCATGGCATGCCAAGGTCCATCTGGTTGGTATTG  
C K I V E M S T S K T G K H G H A K V H L V G I  
ATATTTTTACTGGGAAGAAATATGAAGATATCTGCCCGTCACTCATAACATGGATGTCCCCAACATCAAAA  
D I F T G K K Y E D I C P S T H N M D V P N I K  
GGAATGATTCCAGCTGATTGGCATCCAGGATGGGTACCTATCCCTGCTCCAGGACAGTGGGGAGGTACGAG  
R N D F Q L I G I Q D G Y L S L L Q D S G E V R  
AGGACCTTCGTCTGCCTGAGGGAGACCTTGGCAAGGAGATTGAGCAGAAGTATGACTGTGGAGAAGAGATCC  
E D L R L P E G D L G K E I E Q K Y D C G E E I  
TGATCACAGTGCTGTCCGCCATGACAGAGGAGGCAGCTGTTGCAATCAAGGCTCGAG  
L I T V L S A M T E E A A V A I K A

(488 NT, 151 aa)

**FIG.2**

CAGGTCTAGAGTTGGAATCGAAGCCTCTAAAATGGCAGATGATTGGACTTCGAGACAGGAGATGCAGGGG	
M A D D L D F E T G D A G	13
CCTCAGCCACCTTCCCAATGCAGTGCTCAGCATTACGTAAGAATGGTTTGTGGTGCCTCAAGGGCCGGCCAT	144
A S A T F P M Q C S A L R K N G F V V L K G R P	
GTAAGATCGTCGAGATGTCCTACTTCGAAGACTGGCAAGCATGGCCATGCCAAGGTCATCTGGTTGGTATTG	
C K I V E M S T S K T G K H G H A K V H L V G I	61
ATATTTTACTGGGAAGAAAATATGAAGATATCTGCCCGTCACTCATAACATGGATGTCCCCAACATCAAAA	288
D I F T G K K Y E D I C P S T H N M D V P N I K	
GGAATGATTCAGCTGATTGGCATCCAGGATGGTACCTATCCCTGCTCCAGGACAGTGGGGAGGTACGAG	
R N D F Q L I G I Q D G Y L S L L Q D S G E V R	109
AGGACCTTCGTCTGCCAGGGAGACCTGGCAAGGAGATTGAGCAGAAGTATGACTGTGGAGAAGAGATCC	432
E D L R L P E G D L G K E I E Q K Y D C G E E I	
TGATCACAGTGCTGTCCGCCATGACAGAGGGCAGCTGGCAATCAAGGCCATGGCAAAATACTGGCTT	
L I T V L S A M T E E A A V A I K A M A K *	154
CCAGGGTGGCGGTGGTGGCAGCAGTGATCCATGAGCCTACAGAGGCCCTCCCCAGCTCTGGCTGGCCCT	576
TGGCTGGACTCCATCCAATTATTGACGTTTATTTGGTTTCTCACCCCTCAAACTGTGGGGAGA	
CCCTGCCCTCACCTAGCTCCCTGGCCAGGCATGAGGGAGCCATGGCCTGGTGAAGCTACCTGCCTCTC	720
TCTCGCAGCCCTGATGGGGAAAGGGAGTGGTACTGCCTGTGGTTAGGTTCCCTCTCCCTTTCTT	
TAATTCAATTGGAAATCAGAAAGCTGTGGATTCTGGCAAATGGCTTGTGCTTTATCCACTCAAACCA	864
TCTGGTCCCTGTTCTCCATAGTCCTCACCCCCAAGCACCCTGACAGACTGGGGACAGCCCCCTCC	
GCCTGTGTCTTCCAAACCCCTATAGGGGTGACAAGAAGAGGGGGGGAGGGGACACGATCCCTCC	1008
TCAGGCATCTGGGAAGGCCCTGCCCATGGCTTACCCCTGTGGCTTCTCCGTACACATTGT	
AAAAAATCAAACCTGAATAAAACTACAAGTTAATATGAAAAAAAAAAAAAA	1139

(1139 NT, 154 aa)

FIG.3

4/50

GCTGTGTATTATTGGGCCATAAGAACACATACCTGTGCTGAGTCCTGCACTCACAGACGGCTCACTGGGT  
A V Y Y W A H K N H I P V L S P A L T D G S L G  
GACATGATCTTTCCATT CCTATAAAAACCCAGGCTTGGTCTGGACATCGTGAAGACCTGC GGCTCATC  
D M I F F H S Y K N P G L V L D I V E D L R L I  
AACATGCAGGCCATTTGCCAAGCGCACTGGGATGATCATCCTGGGTGGAGGCGTGGTCAAGCACCACATC  
N M Q A I F A K R T G M I I L G G G V V K H H I  
GCCAATGCTAACCTCATGCCAATGGAGCTGACTACGCTTTATATCAACACAGCCCAGGAGTTGATGGC  
A N A N L M R N G A D Y A V Y I N T A Q E F D G  
TCAGACTCAGGAGCCGGCCAGATGAGGCTGTCTGGGGCAAGATCCGGATGGATGCACAGCCAGTAAAG  
S D S G A R P D E A V S W G K I R M D A Q P V K  
GTCTATGCTGATGCATCTCTGGTTTCCCCTTGCTGGTGGCTGAGACATTGCCAAAAGGCAGATGCCCTC  
V Y A D A S L V F P L L V A E T F A Q K A D A F  
AGAGCTGAGAAGAATGAGGACTGAGCAGATGGTAAAGACGGAGGCTCTGCCACACCTTATTATTATT  
R A E K N E D  
GCATACCAACCCCTCCTGGGCCCTCTCCTGGTCAGCAGCATCTTGAGAATAATGGCCTTTTGTGGTT  
CTGTAAAAAAAGGACTTAAAAAA

(606 NT, 151 aa)

FIG.4

5/50

rat vs. human(BC000751 or NM\_001970) 96.5% identity (coding)

	10	20	30	40	50	60
rat	ATGGCAGATGATTGGACTTCGAGACAGGAGATGCAGGGCCTCAGCCACCTCCCAATG	::::::::::::::::::: ::::::::::::::::::::: :::::::::::::::::::::				
human	ATGGCAGATGACTGGACTTCGAGACAGGAGATGCAGGGCCTCAGCCACCTCCCAATG	10	20	30	40	50
	70	80	90	100	110	120
rat	CAGTGCTCAGCATTACGTAAAGAATGGTTTGTTGCTCAAAGGCCGGCCATGTAAGATC	::::::::::::::::::: ::::::::::::::::::::: :::::::::::::::::::::				
human	CAGTGCTCAGCATTACGTAAAGAATGGCTTGTTGCTCAAAGGCCGGCCATGTAAGATC	70	80	90	100	110
	130	140	150	160	170	180
rat	GTCGAGATGTCTACTTCGAAGACTGGCAAGCATGGCCATGCCAAGGTCCATCTGGTTGGT	::::::::::::::::::: ::::::::::::::::::::: :::::::::::::::::::::				
human	GTCGAGATGTCTACTTCGAAGACTGGCAAGCACGGCACGCCAAGGTCCATCTGGTTGGT	130	140	150	160	170
	190	200	210	220	230	240
rat	ATTGATATTTTACTGGGAAGAAATATGAAGATATCTGCCCGTCACTCATAACATGGAT	::::: :: ::::::::::::: ::::::::::::::::::::: ::::::: :::::::				
human	ATTGACATCTTACTGGGAAGAAATATGAAGATATCTGCCCGTCAACTCATAAATATGGAT	190	200	210	220	230
	250	260	270	280	290	300
rat	GTCCCCAACATCAAAAGGAATGATTCCAGCTGATTGGCATCCAGGATGGGTACCTATCC	::::::::::::::::::: ::::::::::::::::::::: :::::::::::::::::::::				
human	GTCCCCAACATCAAAAGGAATGACTTCAGCTGATTGGCATCCAGGATGGGTACCTATCA	250	260	270	280	290
	310	320	330	340	350	360
rat	CTGCTCCAGGACAGTGGGGAGGTACGAGAGGACCTTCGTCTGCCTGAGGGAGACCTTGGC	::::::::::::::::::: ::::::::::::::::::::: :::::::::::::::::::::				
human	CTGCTCCAGGACAGCGGGGAGGTACGAGAGGACCTTCGTCTCCCTGAGGGAGACCTTGGC	310	320	330	340	350
	370	380	390	400	410	420
rat	AAGGAGATTGAGCAGAAGTATGACTGTGGAGAAGAGATCCTGATCACAGTGCTGTCCGCC	::::::::::::::::::: ::::::::::::::::::::: ::::::: :::::::				
human	AAGGAGATTGAGCAGAAGTACGACTGTGGAGAAGAGATCCTGATCACGGTGCTGTCTGCC	370	380	390	400	410
	430	440	450	460		
rat	ATGACAGAGGAGGCAGCTGTTGCAATCAAGGCCATGGCAAAA	::::::::::::::::::: ::::::::::::::::::::: ::::::: :::::::				
human	ATGACAGAGGAGGCAGCTGTTGCAATCAAGGCCATGGCAAAA	430	440	450	460	

FIG.5

6/50

rat vs. human(NM\_020390) 72.5% identity (coding)

FIG. 6

7/50

rat vs. mouse (BC003889) 98.3% identity (coding)

	10	20	30	40	50	60
rat	ATGGCAGATGATTTGGACTTCGAGACAGGAGATGCAGGGGCCTCAGCCACCTTCCAATG	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::
mouse	ATGGCAGATGATTTGGACTTCGAGACAGGAGATGCAGGGGCCTCAGCCACCTTCCAATG	10	20	30	40	50
	70	80	90	100	110	120
rat	CAGTGCTCAGCATTACGTAAGAACATGGTTTGTTGGTGCCTAAGGGCCGGCCATGTAAGATC	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::
mouse	CAGTGCTCAGCATTACGTAAGAACATGGTTTGTTGGTGCCTAAGGGCCGGCCATGTAAGATC	70	80	90	100	110
	130	140	150	160	170	180
rat	GTCGAGATGTCTACTTCGAAGACTGGCAAGCATTGGCCATGCCAAGGTCCATCTGGTTGGT	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::
mouse	GTCGAGATGTCTACTTCGAAGACTGGCAAGCATTGGCCATGCCAAGGTCCATCTGGTTGGC	130	140	150	160	170
	190	200	210	220	230	240
rat	ATTGATATTTTACTGGGAAGAACATATGAAGATATCTGCCGTGACTCATAACATGGAT	:::::::::::	:::::::::::	:::::::::::	:::::::::::	:::::::::::
mouse	ATTGACATTTTACTGGGAAGAACATATGAAGATATCTGCCGTGACTCATAAATATGGAT	190	200	210	220	230
	250	260	270	280	290	300
rat	GTCCCCAACATCAAAAGGAATGATTTCCAGCTGATTGGCATCCAGGATGGGTACCTATCC	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::
mouse	GTCCCCAACATCAAACGGAATGACTTCCAGCTGATTGGCATCCAGGATGGGTACCTATCC	250	260	270	280	290
	310	320	330	340	350	360
rat	CTGCTCCAGGACAGTGGGGAGGTACGAGAGGACCTTCGTCTGCCTGAGGGAGACCTTGGC	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::
mouse	CTGCTCCAGGACAGTGGGGAGGTACGAGAGGACCTTCGTCTGCCTGAAGGGAGACCTTGGC	310	320	330	340	350
	370	380	390	400	410	420
rat	AAGGAGATTGAGCAGAAGTATGACTGTGGAGAAGAGATCCTGATCACAGTGCTGTCCGCC	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::	:::
mouse	AAGGAGATTGAGCAGAAGTATGACTGTGGAGAAGAGATCCTGATCACAGTGCTGTCTGCC	370	380	390	400	410
	430	440	450	460		
rat	ATGACAGAGGAGGCAGCTGTTGCAATCAAGGCCATGGCAAAA	:::::::::::::::::::	:::::::::::::::::::	:::::::::::::::::::		
mouse	ATGACAGAGGAGGCAGCTGTTGCAATCAAGGCCATGGCAAAA	430	440	450	460	

FIG.7

rat vs. human(BC000751 or NM\_001970) 100.0% identity

	10	20	30	40	50	60
rat	MADDLD <b>FETGDAGASATFPMQCSALRKNGFVVLKGRPCKIVEMSTS</b> KTGKHGHAKVHLVG	::::::	::::::	::::::	::::::	::::::
human	MADDLD <b>FETGDAGASATFPMQCSALRKNGFVVLKGRPCKIVEMSTS</b> KTGKHGHAKVHLVG	::::::	::::::	::::::	::::::	::::::
	10	20	30	40	50	60
rat	IDIFTGKKY <b>EDICPSTHNMDV</b> PNIKRND <b>FQLIGI</b> QDG <b>YLSLLQDS</b> GEV <b>REDLRLPEGDLG</b>	::::::	::::::	::::::	::::::	::::::
human	IDIFTGKKY <b>EDICPSTHNMDV</b> PNIKRND <b>FQLIGI</b> QDG <b>YLSLLQDS</b> GEV <b>REDLRLPEGDLG</b>	::::::	::::::	::::::	::::::	::::::
	70	80	90	100	110	120
rat	KEIEQKY <b>DCGEEILITV</b> LSAM <b>TEEA</b> AVAIKAMAK	::::::	::::::	::::::	::::::	::::::
human	KEIEQKY <b>DCGEEILITV</b> LSAM <b>TEEA</b> AVAIKAMAK	::::::	::::::	::::::	::::::	::::::
	130	140	150			
rat	130	140	150			
human	130	140	150			

FIG.8

9/50

rat vs. human(NM\_020390) 82.5% identity

	10	20	30	40	50	60
rat	MADDLDFETGDAGASATFPMQCSALRKNGFVVLKGRPCKIVEMSTS	KTGK	HGHAKVHLVG			
	:::::::	:::::::	:::::::	:::::::	:::::::	:::::::
human	MADEIDFTTGAGASSTYPMQCSALRKNGFVVLKGRPCKIVEMSTS	KTGK	HGHAKVHLVG			
	10	20	30	40	50	60
	70	80	90	100	110	120
rat	IDIFTGKKYEDICPSTHNM	DVPNIKRND	FQLIGI	QDG	YLSLLQDS	GEVREDLRLPEGDLG
	:::::::::::	:::::::::::	:::::::::::	:::::::::::	:::::::::::	:::::::::::
human	IDIFTGKKYEDICPSTHNM	DVPNIKRNDY	QLICI	QDG	YLSLLTET	GEVREDLKLPEGELG
	70	80	90	100	110	120
	130	140	150			
rat	KEIEQKYDCGEEILITV	L	SAMTE	EEAVAIKAMAK		
	::::	:::	...:	...:	...:	..:
human	KEIEGKYNAGEDVQVSVM	CAM	SEEYAVAI	KP-CK		
	130	140	150			

FIG.9

10/50

rat vs. mouse (BC003889) 100.0% identity

	10	20	30	40	50	60
rat	MADDLDFETGDAGASATFPMQCSALRKNGFVVLKGRPCKIVEMSTS	KTGK	HAKVHLVG			
	::::::::::	::::::::::	::::::::::	::::::::::	::::::::::	::::::::::
mouse	MADDLDFETGDAGASATFPMQCSALRKNGFVVLKGRPCKIVEMSTS	KTGK	HAKVHLVG			
	10	20	30	40	50	60
	70	80	90	100	110	120
rat	IDIFTGKKYEDICPSTHNM	DVPNIKRND	FQLIGI	QDG	YLS	LLQDS
	::::::::::	::::::::::	::::::::::	::::::::::	::::::::::	::::::::::
mouse	IDIFTGKKYEDICPSTHNM	DVPNIKRND	FQLIGI	QDG	YLS	LLQDS
	70	80	90	100	110	120
	130	140	150			
rat	KEIEQKYDCGEEILITV	L	SAMTE	EEAAV	AIKAM	AK
	::::::::::	::::::::::	::::::::::	::::::::::	::::::::::	::::::::::
mouse	KEIEQKYDCGEEILITV	L	SAMTE	EEAAV	AIKAM	AK
	130	140	150			

FIG. 10

rat vs. human (BC000333) 87.4% identity (coding)

	10	20	30	40	50	60
rat	GCTGTATTATTGGGCCATAAGAACACATACCTGTGCTGAGTCCTGCACACAGAC					
	: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: :::::::					
human	TCCGTATTACTGGGCCAGAAGAACACATCCCTGTGTTAGTCCCACAGAC					
	10   20   30   40   50   60					
	70   80   90   100   110   120					
rat	GGCTCACTGGGTGACATGATCTTCCATTCCATAAAAACCCAGGCTGGTCTGGAC					
	: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: :::::::					
human	GGCTCGCTGGCGACATGATCTTCCATTCCATAAGAACCCGGGCTGGTCTGGAC					
	70   80   90   100   110   120					
	130   140   150   160   170   180					
rat	ATCGTTGAAGACCTGCGGCTCATCAACATGCAGGCCATTTCGCCAAGCGCACTGGGATG					
	: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: :::::::					
human	ATCGTTGAGGACCTGAGGCTCATCAACACACAGGCCATTGCCAAGTGCACTGGGATG					
	130   140   150   160   170   180					
	190   200   210   220   230   240					
rat	ATCATCCTGGGTGGAGGCCTGGTCAAGCACACATGCCAATGCTAACCTCATGCGGAAT					
	: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: :::::::					
human	ATCATTCTGGCGGGGGCGTGGTCAAGCACACATTGCCAATGCCAACCTCATGCGGAAC					
	190   200   210   220   230   240					
	250   260   270   280   290   300					
rat	GGAGCTGACTACGCTGTTATATCAACACAGCCCAGGAGTTGATGGCTCAGACTCAGGA					
	: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: :::::::					
human	GGGGCCGACTACGCTGTTACATCAACACAGCCCAGGAGTTGATGGCTCTGACTCAGGT					
	250   260   270   280   290   300					
	310   320   330   340   350   360					
rat	GCCCGGCCAGATGAGGCTGTCCTGGGCAAGATCCGGATGGATGCACAGCCAGTAAAG					
	: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: :::::::					
human	GCCCGACCAGACGAGGCTGTCCTGGGCAAGATCCGGTGGATGCACAGCCGTCAAG					
	310   320   330   340   350   360					
	370   380   390   400   410   420					
rat	GTCTATGCTGATGCATCTCTGGTTTCCCCTGGTGGCTGAGACATTGCCAAAAG					
	: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: ::::::: :::::::					
human	GTCTATGCTGACGCCCTGGCTTCCCCCTGCTTGTGGCTGAAACCTTGCCAGAAG					
	370   380   390   400   410   420					
	430   440   450					
rat	GCAGATGCCTTCAGAGCTGAGAACATGAGGAC					
	: ::::::: ::::::: :::::::					
human	ATGGATGCCTTCATGCATGAGAACAGAGGAC					
	430   440   450					

12/50




FIG.12

13/50




FIG.13

14/50




FIG.14

15/50




FIG.15

16/50



FIG. 16

17/50




FIG. 17

18/50




FIG.18

19/50




FIG. 19

20/50

## SOUTHERN BLOT OF RAT GENOMIC DNA

EcoR V

Rat eIF-5A 1139 bp




FIG.20

21/50




FIG.21

22/50




FIG.22

23/50




FIG. 23

24/50




FIG. 24

25/50

ENHANCEMENT OF APOPTOSIS IN COS-7 CELLS  
EXPRESSING SENSE RAT eIF-5A  
(CASPASE ACTIVITY)




FIG. 25

26/50






FIG.26

27/50

Hoescht Staining of Transformed  
COS-7 Cells Deprived of Serum



Mock Transformed



pHm6-Sense rat F5A

FIG.27

28/50







FIG. 28

29/50



Sense rF5A 20 X



Mock Transfected 20 X




FIG.29

30/50




FIG. 30

31/50




FIG. 31

32/50




FIG.32

33/50





FIG. 33

34/50

Bcl-2 Expression Levels in Transiently Transfected COS-7  
Cells Serum-Starved for 48 Hours



Bcl-2  
(0.5  $\mu$ g/ $\mu$ l)

FIG.34

35/50




FIG.35

36/50




FIG.36

37/50




FIG.37A

38/50




FIG.37B




FIG.37C

Sequence and Alignment of human eIF5A2 isolated from RKO cells with sequence of human eIF5A2 in Genbank (ACCESSION XM\_113401)

XM_113401	MADEIDFTTG DAGASSTYPM QCSALRKNGF VVLKGRPCKI VEMSTSKTGK
PCR	MADEIDFTTG DAGASSTYPM QCSALRKNGF VVLKGRPCKI VEMSTSKTGK
Consensus	MADEIDFTTG DAGASSTYPM QCSALRKNGF VVLKGRPCKI VEMSTSKTGK

	51	100
XM_113401	HGHAKVHLVG IDIFTGKKYE DICPSTHNMD VPNIKRNDYQ LICIQDGYLS	
PCR	HGHAKVHLVG IDIFTGKKYE DICPSTHNMD VPNIKRNDYQ LICIQDGCLS	
Consensus	HGHAKVHLVG IDIFTGKKYE DICPSTHNMD VPNIKRNDYQ LICIQDGCLS	

	101	150
XM_113401	LLTETGEVRE DLKLPEGELG KEIEGKYNAG EDVQVSVMCA MSEYAYAIK	
PCR	LLTETGEVRE DLKLPEGELG KEIEGKYNAG EDVQVSVMCA MSEYAYAIK	
Consensus	LLTETGEVRE DLKLPEGELG KEIEGKYNAG EDVQVSVMCA MSEYAYAIK	

	151
XM_113401	PCK
PCR	PCK
Consensus	PCK

FIG.38

40/50




FIG.39

41/50




FIG.40

42/50




FIG.41

43/50


TRANSFECTION VECTOR

FIG. 42A

TRANSFECTED PLASMID	PERCENT APOPTOSIS
UNTRANSFECTED	21.2%
pHM6-Lac Z	21.7%
pHM6-eIF5A1	60.7% (80%)*
pHM6-eIF5A2	20.5%
pHM6-TRUNCATED eIF5A1	24.1%

\*CORRECTED FOR BACKGROUND APOPTOSIS IN UNTRANSFECTED CELLS AND FOR TRANSFECTION EFFICIENCY

FIG. 42B

44/50




FIG.43

45/50




FIG. 44

46/50




FIG. 45

47/50




FIG. 46




FIG. 47

■ HEATED TO 37°C

49/50




FIG. 48

50/50




FIG. 49

1  
SEQUENCE LISTING

<110> THOMPSON, JOHN E.  
TAYLOR, CATHERINE  
CLICHE, DOMINIC  
DINARELLO, CHARLES  
REZNIKOV, LEONID  
POMERANTZ, BENJAMIN

<120> NUCLEIC ACIDS, POLYPEPTIDES AND METHODS FOR MODULATING APOPTOSIS

<130> 10799/100

<140>

<141> 2003-10-22

<150> 10/277,969  
<151> 2002-10-23

<160> 30

<170> PatentIn Ver. 2.1

<210> 1  
<211> 1139

<212> DNA  
<213> *Rattus* sp.

<220>

<221> CDS  
<222> (33)

<400> 1

caggctctaga gttgaaatcg aagcctctta aa atg gca gat gat ttg gac ttc 53  
Met Ala Asp Asp Leu Asp Phe  
1 5

gag aca gga gat gca ggg gcc tca gcc acc ttc cca atg cag tgc tca 101  
 Glu Thr Gly Asp Ala Gly Ala Ser Ala Thr Phe Pro Met Gln Cys Ser  
                   10                  15                  20

```

gca tta cgt aag aat ggt ttt gtg gtg ctc aag ggc cgg cca tgt aag 149
Ala Leu Arg Lys Asn Gly Phe Val Val Leu Lys Gly Arg Pro Cys Lys
      25           30           35

```

atc gtc gag atg tct act tcg aag act ggc aag cat ggc cat gcc aag 197  
 Ile Val Glu Met Ser Thr Ser Lys Thr Gly Lys His Gly His Ala Lys  
 40 45 50 55

gtc cat ctg gtt ggt att gat att ttt act ggg aag aaa tat gaa gat 245  
 Val His Leu Val Gly Ile Asp Ile Phe Thr Gly Lys Lys Tyr Glu Asp  
                   60                  65                  70

atc tgc ccg tcg act cat aac atg gat gtc ccc aac atc aaa agg aat 293  
 Ile Cys Pro Ser Thr His Asn Met Asp Val Pro Asn Ile Lys Arg Asn  
                  75                 80                 85

gat ttc cag ctg att ggc atc cag gat ggg tac cta tcc ctg ctc cag 341  
 Asp Phe Gln Leu Ile Gly Ile Gln Asp Gly Tyr Leu Ser Leu Leu Gln  
                  90                 95                 100

```

gac agt ggg gag gta cga gag gac ctt cgt ctg cct gag gga gac ctt 389
Asp Ser Gly Glu Val Arg Glu Asp Leu Arg Leu Pro Glu Gly Asp Leu
105          110          115

```

ggc aag gag att gag cag aag tat gac tgt gga gaa gag atc ctg atc 437  
 Gly Lys Glu Ile Glu Gln Lys Tyr Asp Cys Gly Glu Glu Ile Leu Ile  
 120 125 130 135  
  
 aca gtg ctg tcc gcc atg aca gag gag gca gct gtt gca atc aag gcc 485  
 Thr Val Leu Ser Ala Met Thr Glu Glu Ala Ala Val Ala Ile Lys Ala  
 140 145 150  
  
 atg gca aaa taactggctt ccagggtggc ggtgggtggca gcagtgtatcc 534  
 Met Ala Lys  
  
 atgagcctac agaggccctt ccccccagctc tggctgggcc cttggctgga ctccttatcca 594  
 atttatttga cgttttatcc ttggtttcctt cacccttca aactgtcggtt gagaccctgc 654  
 ccttcaccta gctcccttgg ccaggcatga gggagccatg gccttggtga agctacctgc 714  
 ctcttctctc gcagccctga tggggaaag ggagtggta ctgcctgtgg ttttaggttcc 774  
 cctctccctt ttcttttta attcaatttga attcagaaaa gctgtggatt ctggcaaatg 834  
 gtcttgtgtc ctttatccca ctcaaaccctt tctggtcccc tggctccat agtccttcac 894  
 ccccaagcac cactgacaga ctggggacca gcccccttcc ctgcctgtgt ctcttcccaa 954  
 acccctctat aggggtgaca agaagaggag ggggggaggg gacacgatcc ctcctcaggc 1014  
 atctggaaag gccttgcctt catggctttt accctttccat gtggctttc tccctgacac 1074  
 atttggtaaa aatcaaacctt gaataaaaactt acaagttaa tatgaaaaaaa aaaaaaaaaa 1134  
 aaaaaa 1139

<210> 2  
 <211> 154  
 <212> PRT  
 <213> Rattus sp.

<400> 2  
 Met Ala Asp Asp Leu Asp Phe Glu Thr Gly Asp Ala Gly Ala Ser Ala  
 1 5 10 15  
  
 Thr Phe Pro Met Gln Cys Ser Ala Leu Arg Lys Asn Gly Phe Val Val  
 20 25 30  
  
 Leu Lys Gly Arg Pro Cys Lys Ile Val Glu Met Ser Thr Ser Lys Thr  
 35 40 45  
  
 Gly Lys His Gly His Ala Lys Val His Leu Val Gly Ile Asp Ile Phe  
 50 55 60  
  
 Thr Gly Lys Lys Tyr Glu Asp Ile Cys Pro Ser Thr His Asn Met Asp  
 65 70 75 80  
  
 Val Pro Asn Ile Lys Arg Asn Asp Phe Gln Leu Ile Gly Ile Gln Asp  
 85 90 95  
  
 Gly Tyr Leu Ser Leu Leu Gln Asp Ser Gly Glu Val Arg Glu Asp Leu  
 100 105 110  
  
 Arg Leu Pro Glu Gly Asp Leu Gly Lys Glu Ile Glu Gln Lys Tyr Asp  
 115 120 125

3

Cys Gly Glu Glu Ile Leu Ile Thr Val Leu Ser Ala Met Thr Glu Glu  
 130 135 140

Ala Ala Val Ala Ile Lys Ala Met Ala Lys  
 145 150

<210> 3  
 <211> 462  
 <212> DNA  
 <213> Homo sapiens

<400> 3  
 atggcagatg acttggactt cgagacagga gatgcagggg cctcagccac cttcccaatg 60  
 cagtgcctcg cattacgtaa gaatggcttt gtgggtctca aaggccggcc atgtaagatc 120  
 gtcgagatgt ctacttcgaa gactggcaag cacggccacg ccaagggtcca tctgggtgg 180  
 attgacatct ttacttggaa gaaatatgaa gatatctgcc cgtcaactca taatatggat 240  
 gtcccccaaca tcaaaaaggaa tgacttccag ctgattggca tccaggatgg gtacctatca 300  
 ctgctccagg acagcgggaa ggtacgagag gacccctcgcc tccctgaggg agaccttggc 360  
 aaggagattg agcagaagta cgactgtgga gaagagatcc tgatcacggc gctgtctgcc 420  
 atgacagagg aggcagctgt tgcaatcaag gccatggcaa aa 462

<210> 4  
 <211> 462  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> modified\_base  
 <222> (455)..(456)  
 <223> a, t, c or g

<400> 4  
 atggcagacg aaatttgcattt cactactgga gatgccgggg cttccagcac ttaccctatg 60  
 cagtgcctcg ctttgcgcaa aaacggcttc gtgggtctca aaggacgacc atgcaaaata 120  
 gtggagatgt caacttccaa aactggaaag catggtcatg ccaagggttca ctttggatgg 180  
 attgatattt tcacgggcaa aaaatatgaa gatatttgc tttctactca caacatggat 240  
 gttccaaata ttaagagaaa tgattatcaa ctgatatgca ttcaagatgg ttaccttcc 300  
 ctgctgacag aaactgggtga agttcggtgag gatcttaaac tgccagaagg tgaacttaggc 360  
 aaagaaatag aggaaaata caatgcaggt gaagatgtac aggtgtctgt catgtgtgca 420  
 atgagtgaag aatatgctgt agccataaaa ccctnngcaa at 462

<210> 5  
 <211> 462  
 <212> DNA  
 <213> Rattus sp.

<400> 5  
 atggcagatg atttggactt cgagacagga gatgcagggg cctcagccac cttcccaatg 60  
 cagtgcctcg cattacgtaa gaatggtttt gtgggtctca aaggccggcc atgtaagatc 120  
 gtcgagatgt ctacttcgaa gactggcaag catggccatg ccaagggttca tctgggtggc 180  
 attgacattt ttacttggaa gaaatatgaa gatatctgcc cgtcgactca taatatggat 240  
 gtcccccaaca tcaaacggaa tgacttccag ctgattggca tccaggatgg gtacctatcc 300  
 ctgctccagg acagcgggaa ggtacgagag gacccctcgcc tccctgaggg agaccttggc 360  
 aaggagattg agcagaagta tgactgtgga gaagagatcc tgatcacagt gctgtctgcc 420  
 atgacagagg aggcagctgt tgcaatcaag gccatggcaa aa 462

<210> 6  
 <211> 606  
 <212> DNA  
 <213> Rattus sp.

<220>  
 <221> CDS  
 <222> (1)..(453)

<400> 6

gct	gtg	tat	tat	tgg	gcc	cat	aag	aac	cac	ata	cct	gtg	ctg	agt	cct	48
Ala	Val	Tyr	Tyr	Trp	Ala	His	Lys	Asn	His	Ile	Pro	Val	Leu	Ser	Pro	
1	.	5								10				15		

gca ctc aca gac ggc tca ctg ggt gac atg atc ttt ttc cat tcc tat

Ala	Leu	Thr	Asp	Gly	Ser	Leu	Gly	Asp	Met	Ile	Phe	Phe	His	Ser	Tyr	96
															20	
														25		
														30		

aaa aac cca ggc ttg gtc ctg gac atc gtt gaa gac ctg cgg ctc atc

Lys	Asn	Pro	Gly	Leu	Val	Leu	Asp	Ile	Val	Glu	Asp	Leu	Arg	Leu	Ile	144
															35	
														40		
														45		

aac atg cag gcc att ttc gcc aag cgc act ggg atg atc atc ctg ggt

Asn	Met	Gln	Ala	Ile	Phe	Ala	Lys	Arg	Thr	Gly	Met	Ile	Ile	Leu	Gly	192
															50	
														55		
														60		

gga ggc gtg gtc aag cac cac atc gcc aat gct aac ctc atg cgg aat

Gly	Gly	Val	Val	Lys	His	His	Ile	Ala	Asn	Ala	Asn	Leu	Met	Arg	Asn	240
															65	
														70		
														75		
														80		

gga gct gac tac gct gtt tat atc aac aca gcc cag gag ttt gat ggc

Gly	Ala	Asp	Tyr	Ala	Val	Tyr	Ile	Asn	Thr	Ala	Gln	Glu	Phe	Asp	Gly	288
															85	
														90		
														95		

tca gac tca gga gcc cggtt cca gat gag gct gtc tcc tgg ggc aag atc

Ser	Asp	Ser	Gly	Ala	Arg	Pro	Asp	Glu	Ala	Val	Ser	Trp	Gly	Lys	Ile	336
															100	
														105		
														110		

cggtt atg gat gca cag cca gta aag gtc tat gct gat gca, tct ctg gtt

Arg	Met	Asp	Ala	Gln	Pro	Val	Lys	Val	Tyr	Ala	Asp	Ala	Ser	Leu	Val	384
															115	
														120		
														125		

ttc ccc ttg ctg gtg gct gag aca ttc gcc caa aag gca gat gcc ttc

Phe	Pro	Leu	Leu	Val	Ala	Glu	Thr	Phe	Ala	Gln	Lys	Ala	Asp	Ala	Phe	432
															130	
														135		
														140		

aga gct gag aag aat gag gac tgagcagatg ggtaaagacg gaggcttctg

Arg	Ala	Glu	Lys	Asn	Glu	Asp	483	
								145
								150

ccacaccccccatttttttttgcataccaa cccctcctgg gccctctcct tggcagcag 543

catcttgaga ataaaatggcc tttttgttgg tttctgtaaa aaaaggactt taaaaaaaaa 603

aaa 606

<210> 7  
 <211> 151  
 <212> PRT  
 <213> Rattus sp.

<400> 7

Ala	Val	Tyr	Tyr	Trp	Ala	His	Lys	Asn	His	Ile	Pro	Val	Leu	Ser	Pro	490
1	.	5								10					15	

Ala Leu Thr Asp Gly Ser Leu Gly Asp Met Ile Phe Phe His Ser Tyr

20										25					30	
----	--	--	--	--	--	--	--	--	--	----	--	--	--	--	----	--

5

Lys Asn Pro Gly Leu Val Leu Asp Ile Val Glu Asp Leu Arg Leu Ile  
 35 40 45

Asn Met Gln Ala Ile Phe Ala Lys Arg Thr Gly Met Ile Ile Leu Gly  
 50 55 60

Gly Gly Val Val Lys His His Ile Ala Asn Ala Asn Leu Met Arg Asn  
 65 70 75 80

Gly Ala Asp Tyr Ala Val Tyr Ile Asn Thr Ala Gln Glu Phe Asp Gly  
 85 90 95

Ser Asp Ser Gly Ala Arg Pro Asp Glu Ala Val Ser Trp Gly Lys Ile  
 100 105 110

Arg Met Asp Ala Gln Pro Val Lys Val Tyr Ala Asp Ala Ser Leu Val  
 115 120 125

Phe Pro Leu Leu Val Ala Glu Thr Phe Ala Gln Lys Ala Asp Ala Phe  
 130 135 140

Arg Ala Glu Lys Asn Glu Asp  
 145 150

&lt;210&gt; 8

&lt;211&gt; 453

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

tccgtgtatt actggggccca gaagaaccac atccctgtgt ttagtccgc acttacagac 60  
 ggctcgctgg gogacatgat cttcttccat tcctacaaga acccgccct ggccctggac 120  
 atcggtgagg acctgaggct catcaacaca caggccatct ttgccaagtg cactggatg 180  
 atcattctgg gccccggcgt ggtcaagcac cacattgcca atgccaacct catgcggAAC 240  
 ggggcccact acgctgttta catcaacaca gcccaggagt ttgatggctc tgactcagg 300  
 gccccaccag acgaggcgtgt ctccctgggc aagatccggg tggatgcaca gcccgtcaag 360  
 gtctatgctg acgcctccct ggtcttcccc ctgcgtgtgg ctgaaacctt tgcccagaag 420  
 atggatgcct tcatgcatga gaagaacgag gac 453

&lt;210&gt; 9

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Primer

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (12)

&lt;223&gt; a, t, c or g

&lt;400&gt; 9

tcsaarachg gnaagcaygg

20

&lt;210&gt; 10

&lt;211&gt; 42

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

6

<223> Description of Artificial Sequence: Primer

<400> 10  
gcgaagcttc catggctcga gttttttttt tttttttttt tt 42

<210> 11  
<211> 972  
<212> DNA  
<213> *Rattus* sp.

<220>  
<221> CDS  
<222> (1)..(327)

<400> 11  
tcg aag acc ggt aag cac ggc cat gcc aag gtc cat ctg gtt ggt att 48  
Ser Lys Thr Gly Lys His Gly His Ala Lys Val His Leu Val Gly Ile  
1 5 10 15

gat att ttt act ggg aag aaa tat gaa gat atc tgc ccg tcg act cat 96  
Asp Ile Phe Thr Gly Lys Lys Tyr Glu Asp Ile Cys Pro Ser Thr His  
20 25 30

aac atg gat gtc ccc aac atc aaa agg aat gat ttc cag ctg att ggc 144  
Asn Met Asp Val Pro Asn Ile Lys Arg Asn Asp Phe Gln Leu Ile Gly  
35 40 45

atc cag gat ggg tac cta tcc ctg ctc cag gac agt ggg gag gta cga 192  
Ile Gln Asp Gly Tyr Leu Ser Leu Leu Gln Asp Ser Gly Glu Val Arg  
50 55 60

gag gac ctt cgt ctg cct gag gga gac ctt ggc aag gag att gag cag 240  
Glu Asp Leu Arg Leu Pro Glu Gly Asp Leu Gly Lys Glu Ile Glu Gln  
65 70 75 80

aag tat gac tgt gga gaa gag atc ctg atc aca gtg ctg tcc gcc atg 288  
Lys Tyr Asp Cys Gly Glu Glu Ile Leu Ile Thr Val Leu Ser Ala Met  
85 90 95

aca gag gag gca gct gtt gca atc aag gcc atg gca aaa taactggctt 337  
Thr Glu Glu Ala Ala Val Ala Ile Lys Ala Met Ala Lys  
100 105

ccaggggtggc ggtgggtggca gcagtgtatcc atgagccctac agaggccctt ccccccagctc 397  
tggctgggccc ctggctggca ctccatccat atttatttta cgtttttattt tggtttccct 457  
cacccttca aactgtcggg gagaccctgc cttcaccta gtccttgg ccaggcatga 517  
gggagccatg gccttggta agtacctgc ctcttcttc gcagccctga tgggggaaag 577  
ggagtgggta ctgcctgtgg tttaggttcc cctctccctt tttttttta attcaattt 637  
gaatcagaaa gctgtggatt ctggcaaattt gtcttgttgc ctttatccca ctcaaaccctt 697  
tctggtcccc tggctccat agtccatcac ccccaagcac cactgacaga ctggggacca 757  
cccccttcc ctgcctgtgt ctcttccaa acccccttat aggggtgaca agaagaggag 817  
ggggggaggg gacacgatcc ctccctcaggc atctggaaag gccttggccc catgggctt 877  
accctttccct gtgggctttc tccctgacac atttgttaaa aatcaaaccct gaataaaaact 937  
acaagtttaa tatgaaaaaaa aaaaaaaaaa aaaaa 972

<210> 12  
 <211> 109  
 <212> PRT  
 <213> Rattus sp.

<400> 12  
 Ser Lys Thr Gly Lys His Gly His Ala Lys Val His Leu Val Gly Ile  
 1 5 10 15

Asp Ile Phe Thr Gly Lys Tyr Glu Asp Ile Cys Pro Ser Thr His  
 20 25 30

Asn Met Asp Val Pro Asn Ile Lys Arg Asn Asp Phe Gln Leu Ile Gly  
 35 40 45

Ile Gln Asp Gly Tyr Leu Ser Leu Leu Gln Asp Ser Gly Glu Val Arg  
 50 55 60

Glu Asp Leu Arg Leu Pro Glu Gly Asp Leu Gly Lys Glu Ile Glu Gln  
 65 70 75 80

Lys Tyr Asp Cys Gly Glu Glu Ile Leu Ile Thr Val Leu Ser Ala Met  
 85 90 95

Thr Glu Glu Ala Ala Val Ala Ile Lys Ala Met Ala Lys  
 100 105

<210> 13  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 13  
 caggtctaga gttggaatcg aagc

24

<210> 14  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 14  
 atatctcgag ccttgattgc aacagctgcc

30

<210> 15  
 <211> 489  
 <212> DNA  
 <213> Rattus sp.

<220>  
 <221> CDS  
 <222> (33)...(485)

<400> 15

caggtctaga gttggaaatcg aaggcttta aa atg gca gat gat ttg gac ttc Met Ala Asp Asp Leu Asp Phe 1 5	8 53
gag aca gga gat gca ggg gcc tca gcc acc ttc cca atg cag tgc tca Glu Thr Gly Asp Ala Gly Ala Ser Ala Thr Phe Pro Met Gln Cys Ser 10 15 20	101
gca tta cgt aag aat ggt ttt gtg gtg ctc aag ggc cgg cca tgt aag Ala Leu Arg Lys Asn Gly Phe Val Val Leu Lys Gly Arg Pro Cys Lys 25 30 35	149
atc gtc gag atg tct act tcg aag act ggc aag cat ggc cat gcc aag Ile Val Glu Met Ser Thr Ser Lys Thr Gly Lys His Gly His Ala Lys 40 45 50 55	197
gtc cat ctg gtt ggt att gat att ttt act ggg aag aaa tat gaa gat Val His Leu Val Gly Ile Asp Ile Phe Thr Gly Lys Lys Tyr Glu Asp 60 65 70	245
atc tgc ccg tcg act cat aac atg gat gtc ccc aac atc aaa agg aat Ile Cys Pro Ser Thr His Asn Met Asp Val Pro Asn Ile Lys Arg Asn 75 80 85	293
gat ttc cag ctg att ggc atc cag gat ggg tac cta tcc ctg ctc cag Asp Phe Gln Leu Ile Gly Ile Gln Asp Gly Tyr Leu Ser Leu Leu Gln 90 95 100	341
gac agt ggg gag gta cga gag gac ctt cgt ctg cct gag gga gac ctt Asp Ser Gly Glu Val Arg Glu Asp Leu Arg Leu Pro Glu Gly Asp Leu 105 110 115	389
ggc aag gag att gag cag aag tat gac tgt gga gaa gag atc ctg atc Gly Lys Glu Ile Glu Gln Lys Tyr Asp Cys Gly Glu Glu Ile Leu Ile 120 125 130 135	437
aca gtg ctg tcc gcc atg aca gag gag gca gct gtt gca atc aag gct Thr Val Leu Ser Ala Met Thr Glu Glu Ala Ala Val Ala Ile Lys Ala 140 145 150	485
cgag	489
 <210> 16 <211> 151 <212> PRT <213> Rattus sp.	
 <400> 16 Met Ala Asp Asp Leu Asp Phe Glu Thr Gly Asp Ala Gly Ala Ser Ala 1 5 10 15	
 Thr Phe Pro Met Gln Cys Ser Ala Leu Arg Lys Asn Gly Phe Val Val 20 25 30	
 Leu Lys Gly Arg Pro Cys Lys Ile Val Glu Met Ser Thr Ser Lys Thr 35 40 45	
 Gly Lys His Gly His Ala Lys Val His Leu Val Gly Ile Asp Ile Phe 50 55 60	
 Thr Gly Lys Lys Tyr Glu Asp Ile Cys Pro Ser Thr His Asn Met Asp 65 70 75 80	
 Val Pro Asn Ile Lys Arg Asn Asp Phe Gln Leu Ile Gly Ile Gln Asp	

<210> 17  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 17  
gtctgtgtat tattggggccc 20

<210> 18  
<211> 42  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 18  
gcgaagcttc catggctcga gttttttttt tttttttttt tt 42

<210> 19  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 19  
ttgaagggtt gaggaaaa 18

<210> 20  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 20  
ttgagtggtt taaag 15

<210> 21

10

<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 21  
aatcatctgc cattttaa

18

<210> 22  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 22  
gccaaagctta atggcagatg atttgg

26

<210> 23  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 23  
ctgaattcca gttattttgc catgg

25

<210> 24  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 24  
aatgaattcc gccatgacacag aggaggc

27

<210> 25  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 25  
aaactaccat ctccccctgcc

20

<210> 26  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

11  
<223> Description of Artificial Sequence: Primer  
<400> 26  
tgccctacac aggctgaaag 20

<210> 27  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer  
<400> 27  
atcaagttg cccaccatgg cagacg 26

<210> 28  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer  
<400> 28  
aacgaattcc atgcctgatg tttccg 26

<210> 29  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer  
<400> 29  
tccgaattcg tacttctgct caatc 25

<210> 30  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 30  
Cys Arg Leu Pro Glu Gly Asp Leu Gly Lys Glu Ile Glu Gln Lys Tyr  
1 5 10 15

Asp